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Thesis abstract 
Diabetes mellitus is a serious worldwide disease characterised by pathological 
metabolism of sugars. Diabetic peripheral neuropathy (DPN) is a common 
complication of diabetes involving dysfunction of peripheral nerves. Diabetes is 
known to alter a number of biomechanical aspects of gait, but it remains unknown 
as to whether these alterations could impact upon the metabolic cost of walking 
(CoW). The aim of this thesis was to investigate the CoW in people with diabetes 
and examine biomechanical factors that could contribute to explaining any potential 
differences. Data were generated from three groups: patients with DPN (n=14), 
patients with diabetes but without peripheral neuropathy (DM, n=22), and controls 
without diabetes (Ctrl, n=31). Gait assessment was performed using a Vicon motion 
analysis system and Kistler force plates while participants walked at a range of 
matched speeds (between 0.6 and 1.6 m/s). Oxygen consumption was measured 
continuously whilst participants walked on a motor-driven treadmill at the range of 
matched walking speeds. Ultrasonographic imaging data from the plantarflexor 
muscle-tendon complex (MTC) were collected in vivo during walking to determine 
MTC properties. Magnetic resonance imaging of the ankle joint in the standing 
position was used to quantify the internal leverage around the ankle. Isometric 
plantarflexor maximal voluntary contraction strength was measured using a 
dynamometer. The CoW was significantly higher in the DPN group across a range 
of matched walking speeds and also in the DM group at selected speeds, compared 
to Ctrl. Despite the higher CoW in patients with diabetes, concentric lower limb joint 
work was significantly lower in DM and DPN groups compared to Ctrl. A greater 
value for the effective mechanical advantage (EMA) at the ankle joint was found in 
the DPN and DM groups compared to Ctrl, meaning that the ankle plantarflexor 
muscles developed relatively lower forces to generate a given joint moment 
compared to Ctrl. The increased EMA was mainly caused by a smaller external 
moment arm of the ground reaction force in the DPN and DM groups compared to 
Ctrl. The DPN group reduced the joint moment at the ankle during walking by 
applying the ground reaction force more proximally on the foot, or at an angle 
directed more towards the ankle, thereby reducing the external moment arm and 
increasing the EMA around the ankle. The DPN group demonstrated significantly 
less Achilles tendon elongation during walking, higher stiffness and higher hysteresis 
compared to Ctrl. These properties mean that the Achilles tendon would store and 
release less energy in the DPN group during walking, requiring more work from the 
plantarflexor muscles. Vertical displacement of the centre of mass during walking 
was not different between groups and is therefore unlikely to be a factor in itself that 
contributes towards the increased CoW in people with diabetic neuropathy. A higher 
cumulative joint work resulting from an increased cadence may contribute to the 
higher CoW in patients with diabetes, along with a reduced elastic energy 
contribution from the Achilles tendon. 
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1. INTRODUCTION 
 
1.1 Introduction to Diabetes mellitus 
Diabetes mellitus (DM) is a serious worldwide endocrinological disease 
characterised by pathological metabolism of sugars. The term diabetes mellitus 
describes a group of chronic metabolic disorders characterised by hyperglycemia 
resulting either from a deficiency of insulin production, or decreased ability to 
transduce the insulin signal (insulin resistance), or both (7). Diabetes is a global 
epidemic with significant morbidity, very common in older people and is often 
undiagnosed (67). Diabetes is associated with a range of serious complications that 
result in reduced quality of life and premature mortality. The prevalence of diabetes 
is increasing at an alarming rate and the condition presents lifelong health problems 
(27). There are four main types of diabetes: 
Type 1 is caused by an autoimmune reaction where the body’s defence system 
attacks the insulin-producing beta cells in the pancreas. Type 1 diabetes is 
developed if the body cannot produce any insulin. Usually appears before the age 
of 40 years. It is the least common of the two main types of diabetes and accounts 
for around 10% of all people with diabetes (35).  
Type 2 diabetes develops when the body can still produce insulin, but this is either 
not sufficient, or the insulin has little or no intended effect (known as insulin 
resistance). This type of diabetes usually appears in people over the age of 40 years, 
though in South Asian and African-Caribbean people, it often appears much earlier, 
appearing typically after the age of 25 years. Type 2 diabetes is the more common 
of the two main types and accounts for around 90% of people with diabetes (34). 
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Type 2 diabetes typically affects patients who are overweight and display lower level 
of physical activity, but evidence suggests that stressful experience might affect 
diabetes, both its onset and its exacerbation (79). Diabetes is a very common 
condition among older adults. Secondary diabetes develops in serious health 
failures such as pancreatic damage, hepatic cirrhosis, endocrinological 
disease/therapy, or anti-viral/anti-psychotic therapy. 
Gestational diabetes is another form of diabetes, affecting pregnant women without 
a previous history of diabetes, but who develop a high blood glucose level during 
pregnancy. Gestational diabetes has a tendency to occur around the 24th week of 
pregnancy and occurs when insulin receptors do not function properly. This is likely 
due to pregnancy-related factors such as the presence of human placental lactogen 
that interferes with susceptible insulin receptors. This in turn causes inappropriately 
elevated blood sugar levels. 
The main complications associated with diabetes are cardiovascular diseases, 
nephropathy, retinopathy and peripheral neuropathy (46) and this will be discussed 
further in one of the following sections. 
 
1.2 Symptoms of DM Type 1 and Type 2. 
There are a variety of symptoms present in diabetes: increased thirst, urinating 
frequently, particularly at night, increased hunger (especially after eating), feeling 
very tired, dry mouth, non-healing skin infections, unexplained weight loss and loss 
of muscle bulk, blurred vision, fatigue, cramps, Itchiness around the genitals and 
recurrent infections including thrush Infections. The three classic symptoms of 
diabetes are thirst, polyuria (excessive urination) and weight loss. As glucose is lost 
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in the urine it draws fluid and other small molecules with it, causing excessive 
urination, which in turn causes dehydration and thirst. Weight is lost because of rapid 
breakdown of fat and protein reserves to compensate for the loss of glucose and 
metabolic inefficiency due to lack of insulin action. The breakdown of protein 
primarily occurs from skeletal muscles, explaining the reduction in body mass 
through muscle atrophy. In most cases the presence of diabetes is associated with 
several of these symptoms occurring together. 
 
1.3 Risk factors and prevalence 
Type 1 diabetes is not currently preventable, while Type 2 is more complex and is a 
combination of genes and life habits (lifestyle) and prevention is certainly possible. 
Simple lifestyle measures have been shown to be effective in preventing or delaying 
the onset of type 2 diabetes (153). 
The main risk factors for developing diabetes are: 
1. Genetics (family history) 
2. Obesity 
3. Sedentary way of life and lack of exercise (hypokinesia) 
4. Stress 
5. Poor nutrition 
6. High blood pressure, heart attack, stroke, coronary diseases 
7. Ethnicity. 
 
The International Diabetes Federation (IDF) estimates that in 2014 the five countries 
with the highest numbers of people with diabetes were India, China, the United 
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States, Russia and Brazil, also low and middle income countries face the greatest 
burden of diabetes. Li et al. (77) shows that the ‘‘top three’’ countries with the 
absolute numbers of people with diabetes are India, China, and the USA. Large 
increases in prevalence are also expected, mostly in countries such as Bangladesh, 
Brazil, Indonesia, Japan, and Pakistan. Among other factors, ethnicity can be one of 
the factors that can decrease or increase risk of developing diabetes. In some cases 
that can be explained by socio-economic factors, studies have shown that even with 
equal access prevalence of diabetes differs between people of different ethnicity. 
The prevalence of adult Type 2 diabetes is about three to five times greater in 
African-Caribbean and South Asian people (Table 1), respectively, compared with 
the white European population. Certain gender differences are present in both type 
1 and 2. Diabetes prevalence among the countries is ranging from 2.4% to 37.5% 
(138, 160, 20). The world health organisation estimates that by 2025 as many as 
200–300 million people worldwide will have developed type 2 diabetes (74). 
Approximately 15% of adult people in developed countries have diabetes. In the 
United Kingdom, 3.2 million people (6% of the total United Kingdom population) have 
been diagnosed with diabetes (67). By 2025, it is predicted that there will be more 
than four million people with diabetes in the United Kingdom (8). An additional 
worldwide problem is undiscovered/undiagnosed diabetes and it is estimated that 
there are up to half a million people in the United Kingdom who have diabetes but 
have not yet been diagnosed. 
 
 
Table 1. Countries with the highest prevalence of diabetes (67). 
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Country % prevalence 
Tokelau 37.5 
Federated States of Micronesia 35.0 
Marshall Islands 34.9 
Cook Islands 25.7 
Saudi Arabia 24.0 
Nauru 23.3 
Kuwait 23.1 
Qatar 22.9 
 
1.4 Financial costs 
In the United Kingdom, it is currently estimated that 10% of the total NHS budget is 
spent on diabetes. This works out at around £9 billion a year (based on 2007/2008 
budget for the NHS of approximately £90.7 billion), or £173 million a week, or £25 
million a day (35). Patients with diabetes require at least two to three times the 
health-care resources to patients without diabetes, and approximately 15% of health 
care budgets are spent on diabetes related care. In 2012, the cost of diabetes to the 
United States of America healthcare system was $245 billion, of which $69 billion 
was due to reduced productivity, and $176 billion was spent on direct medical costs. 
Hex et al. (58) presented the current and the future costs of Type 1 and Type 2 
diabetes in the UK, including direct health costs and indirect societal and productivity 
costs. In their study they estimated total costs screening, testing, treatment, 
management and complications, in 2011 to be £10 billion and estimated cost for 
2035 to increase to £17 billion. 
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1.5 Complications of Diabetes mellitus 
The main complications associated with diabetes are cardiovascular diseases, 
nephropathy, stroke, peripheral arterial disease, retinopathy, skin problems, poor 
wound healing and peripheral neuropathy (43, 46). The prevalence of diabetes is 
increasing because of the ageing population, obesity and sedentary way of life. The 
chronic hyperglycemia is associated with long-term damage, failure or dysfunction 
of many tissues and organs (65). Diabetes can cause peripheral nerve dysfunction, 
which might be one pathway through which diabetes leads to decreased physical 
function, particularly in the lower limbs (97). 
Other complications of diabetes might include foot deformity (146), deterioration in 
the function of large afferent nerve fibres, slow eye movements (57), motor and 
vestibular impairment (121).  
Neuropathies, muscle weakness and balance impairments, either together or 
individually, can lead to gait abnormalities including improper pressure distribution 
on the foot, a longer stance phase and shorter steps than observed in people without 
diabetes (21, 57, 95, 123, 91). These gait and balance impairments in diabetes are 
not simply a matter of academic interest; people with diabetes are fifteen times more 
likely to report experiencing a fall-related injury during standing and walking when 
compared to people without diabetes (118, 139, 36, 118). Although there are many 
complications related to diabetes, this introduction will focus mainly on diabetic 
peripheral neuropathy (DPN), as one of the most significant complications that 
affects gait in people with diabetes. 
1.5.1 Diabetic Peripheral Neuropathy 
Diabetic peripheral neuropathy is a long-term complication and dysfunction of 
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peripheral nerves. The main cause is neurovascular alterations to the nerve fibres 
and blood vessels supplying the nerve endings, resulting in reduced or absent nerve 
conduction (35). The European association for the study of diabetes defines DPN as 
“the presence of symptoms and/or signs of peripheral nerve dysfunction in people 
with diabetes after the exclusion of other causes” (17). The incidence of DPN ranges 
from 13 to 68% in diabetes populations (145, 97, 17). Nerves become damaged and 
people affected by neuropathy are 15 times more likely to experience an injury during 
walking (38, 25). DPN affects the sensory, motor and autonomic components of the 
nervous system, manifesting as a loss of protective sensation, intrinsic foot muscle 
dysfunction and anhidrosis (diminished sweating response) of the foot. Both age and 
duration of diabetes are independent risk factors for DPN. Moreover, neuropathic 
patients walk slower, have longer double support time (two feet in contact with the 
ground), shortened stride lengths, decreased ground reaction forces and decreased 
ankle moments and powers compared to matched controls (21, 57, 116, 96, 73, 37), 
while the impact of diabetes on the cost of walking (CoW) remains unknown. 
Symptoms of DPN may include sensory deficits in light touch and proprioception and 
motor deficits in terms of reduced strength in the ankle muscles. The sensory and 
motor deficits may subsequently result in balance disorders and an increased risk of 
falling (21), which may lead to injuries and hospitalization in this group of patients 
(91). 
 
1.5.2 Diabetic Peripheral Neuropathy and gait impairment 
Patients with diabetic peripheral neuropathy exhibit decreased stability both, while 
standing and during walking (16, 48, 134, 19). Several authors (128, 73) have found 
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gait pattern deviations in diabetic peripheral neuropathy and diabetes mellitus 
patients. For instance, important deviations were revealed in hip, knee, ankle joints 
and trunk movement patterns over the entire stance phase of gait in both DPN and 
DM subjects (128). Fernando et al. (41) presented that DPN participants walked 
slower than healthy control subjects (50, 126, 129) and two studies reported slower 
walking speeds in the DPN group compared to the DM patients (128). DPN-related 
changes in the lower limbs may lead to functional gait variations; predominantly 
related to reduced range of movement of joints, reduced active muscle power and 
changes in gait mechanics (9). Gait related changes and developing foot ulcers are 
very often consequences of neuropathy (143). DPN can have catastrophic 
consequences for patients, as this leads to foot ulceration and increased risk of limb 
amputation, significant healthcare costs, reduced quality of life and reduced mobility 
(41, 17, 135). Handsaker (57) showed that training may favourably alter muscle 
activations and increase the speed of ankle and knee strength development in 
people with DPN, potentially reducing the risk of falling and improving safety during 
the everyday task of stair walking. Therefore, understanding the impact of DPN on 
the biomechanical aspects of human locomotion is clinically important (45). Boulton 
(17) recommends all diabetic patients, regardless of their type of diabetes, duration 
of diabetes, or age, require careful clinical examination of the lower extremities and 
feet at least once a year.  
1.6 Glycation and Diabetes mellitus 
The hallmark of diabetes mellitus, whether Type I or type II, is hyperglycemia. 
Clinical complications associated with diabetes are most likely the consequence of 
hyperglycemia via both altered metabolic pathways and non-enzymatic glycation of 
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proteins. The nonenzymatic glycation of proteins is accelerated in diabetes due to 
elevated blood glucose concentration. The Amadori product of nonenzymatic 
glycation will further cross-link with other proteins to form advanced glycosylation 
end products (158). Advanced glycation end products (AGEs) represent a 
heterogeneous group of chemical products resulting from a non-enzymatic reaction 
between reducing sugars and proteins, lipids, nucleic acids, or a combination of 
these (99). The glycation process (glucose fixation) affects circulating proteins 
(serum albumin, lipoprotein, insulin, hemoglobin), whereas the formation of AGEs 
implicates reactive intermediates such as methylglyoxal. Glycation involves a series 
of reactions in which proteins bind non-enzymatically to reducing sugars such as 
glucose (3, 51). AGEs have been identified in the kidney, nerve, arteries and heart 
of diabetic animals and humans (3, 135, 44, 98) Thus, the accumulation of these 
compounds has been implicated in the etiology of the diabetic complications of 
nephropathy, retinopathy, cataract, neuropathy and accelerated vascular disease 
(137, 44, 98). Hyperglycemia is still considered the principal cause of diabetes 
complications (104). The recognition and binding of AGEs to RAGE contribute to the 
microvascular and macro vascular complications of diabetes. It has been shown in 
animal models of diabetes (111, 112, 113) that non-enzymatic glycation affect other 
tissues such as tendon. This causes increased cross-linking, increasing the stiffness 
and modulus of the tendon. 
1.7 Gait characteristics in people with DM and DPN 
Walking represents the most convenient and the most usual way of transport for 
humans. Walking is one of the most practiced of all motor skills (72). Also walking is 
a popular, convenient and a relatively safe form of exercise (60) that holds great 
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promise for weight management (56, 69). Weight management is most effective 
when individuals can accurately determine how much energy they expend during 
exercise, which, in the case of walking, is dependent on speed (22). In the work of 
Sasaki & Neptune (101) it is suggested that previous studies indicated that the two 
primary energy saving mechanisms in walking are the passive exchange of potential 
and kinetic energy (25) and elastic energy utilization (59). Assuming that walking can 
be modelled as an inverted-pendulum, the maximum theoretical efficiency of the 
energetic exchange between kinetic and potential energy (i.e., energy recovery) is 
only as high as 65% and varies depending on walking speed (26) and stride 
frequency (93). During human gait, the storage and return of elastic energy in 
compliant structures is an important energy saving mechanism that will reduce the 
necessary muscle fibre work and be an important determinant of the preferred gait 
mode (i.e., walk or run) at a given speed. 
The main question this thesis addresses the impact of diabetes and diabetic 
peripheral neuropathy on the CoW. The further questions investigate possible 
mechanisms accounting for any differences in the CoW, including vertical 
displacement of the centre of mass (CoM) and the cadence. 
The purpose of the studies comprising this thesis are to investigate the metabolic 
cost of walking in people with diabetes and further elucidate biomechanical factors 
that alter gait characteristics and that may impact upon the metabolic cost of walking. 
Treadmill walking has frequently been used to assess in older adults due to the 
ability to control walking speed closely (28, 42, 80, 84, 151). It is hypothesized that 
walking at slower speeds (as is the case in diabetes patients) may be mechanically 
less efficient (100). There are many possible factors, which can explain oxygen 
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uptake and the CoW, among them are shorter strides, longer double support time, 
higher values of ground reaction forces, presence of neuropathies and a stiffer 
Achilles tendon. 
It is particularly interesting to investigate, from a biomechanical point of view, what 
is the impact of diabetic peripheral neuropathy and diabetes without neuropathy on 
walking characteristics.  
Walking patterns of diabetic patients are explained in many studies: 
A review of the main aspects of gait in people with diabetes and diabetic neuropathy 
follows:  
1.7.1 Spatio-temporal gait parameters 
The gait speed of diabetes and control patients was described in many studies. The 
self-selected walking speed in diabetic patients has been observed to range from 
0.7 to 1.24 m/s and was significantly lower than that of controls, which ranged from 
0.9 to 1.47 m/s (41, 21, 91, 128, 110). Petrovsky et al. (105) described a significantly 
higher walking speed in controls compared to groups with either type 1 or 2 diabetes. 
Additionally, they assessed slower reaction times in patients with diabetes and a 
much slower gait while turning than compared to control subjects. They 
demonstrated that subjects with type 2 diabetes used an average of two steps to 
turn, whereas control subjects on average used one step. The subjects with type 2 
diabetes took 1.66 s to execute this free pivot, whereas the control subjects took, on 
average, 0.78 s. Stride length findings in diabetes patients has been observed to 
range from 1.04 to 1.38 m and was significantly lower than that of for the Ctrl group, 
which ranged from 1.14 to 1.54 m (127, 129, 95, 87, 30, 37, 91). Step length 
differences between the DPN and the Ctrl groups were well documented in many 
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studies (29, 91, 11, 95, 5, 157), with constant findings of shorter steps in the DPN 
groups. Step-cycle length was described in several studies (36, 37, 38, 95, 91, 57). 
Values ranged from 1.38 to 1.54 m for controls, and from 1.08 to 1.38 m in diabetic 
patients. Cadence (steps/min) at self-selected walking speed has been described in 
many studies (95, 157, 49, 110, 87, 76, 123, 159, 4). All mentioned studies showed 
that the DPN group had a higher cadence compared to the Ctrl group and as the 
main responsible factors were suggested as slower self-selected speed, shorter 
steps and shorter strides. 
 
Table 1. Self-selected walking speed reported from the literature in three different 
participant groups (Ctrl – controls, DM – Diabetes mellitus (without neuropathy), 
DPN – Diabetic Peripheral Neuropathy). 
 Ctrl DM DPN 
 Self-selected walking speed (m/s)  
Sawacha et al. (2009a) 1.27 1.10 1.10 
Sawacha et al. (2009b) 1.00 - 1.00 
Savelberg et al. (2012b) 1.22 1.30 1.40 
Allet et al. (2009) 1.49 1.27 1.19 
Dingwell et al. (2000) 1.47 - 1.24 
Brown et al. (2014) 1.39 1.28 1.22 
Menz et al. (2004) 1.21 - 0.98 
Jor`dan et al. (2014) 1.14 - 1.05 
Raspovic (2013) 1.3 1.4 1.2 
Savelberg et al. (2012a) 1.18 1.06 1.02 
Mueller et al. (1995) 1.26 1.09 - 
Martinelli et al. (2013) 1.03 - 0.89 
Salsich & Mueller (2000) 1.29 - 1.12 
de Mettelinge et al. (2013) 1.38 - 1.04 
Kwon et al. (2013) 0.9  0.7 
 
Gait cycle time has been investigated in various studies. Gait cycle time in diabetic 
patients was in range between 1.15 to 1.26 s, with the time ranging from 1.00 to 1.22 
s for controls (118, 119, 120, 121, 95, 96, 38, 30, 36, 37, 38). Richardson et al. (118) 
showed that environmental factors have a significant effect on all spatio-temporal 
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gait parameters in diabetic subjects. In a challenging environment in which either 
walking surface conditions or lighting intensity was manipulated, a decrease in step 
length and walking speed and an increase in step width, step-width variability, step 
width to step length ratio and step-time variability were observed. Furthermore, the 
controls did not decrease their step length or increase step width in a challenging 
environment, unlike patients with diabetes. Menz et al. (95) found comparable 
results, reporting that the walking speed of patients with DPN was 19% slower while 
walking on a level surface and 25% slower on an irregular surface than among 
healthy controls. 
1.7.2 Kinematics of gait 
Petrovsky et al. (105, 106, 107) compared diabetic patients with and without 
neuropathy to healthy controls and showed that subjects with diabetes walked 
significantly slower than control subjects and with a wider stance (base of support), 
both for walking in a linear path and when making turns. The accelerometers 
measured side-to-side and forward–backward directions. The coefficient of variation 
was higher at the head than the shoulders and higher for the hip than the shoulders 
for both controls and diabetics. However, the coefficient of variation for movement 
was much larger in diabetic patients. Menz et al. (91) found smaller magnitude 
accelerations in patients with diabetes compared to controls and recorded more 
erratic acceleration signals in diabetic patients, particularly at the head. Dingwell et 
al. (36) used a tri-axial accelerometer on the upper body to measure the standard 
deviation of accelerations and reported no difference between diabetic patients with 
neuropathy and healthy controls. Consistently smaller ranges of motion (RoM) at the 
ankle, knee and hip in the DPN group have been reported from a range of studies 
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and likely underlies the shorter step length reported in diabetes patients. Ankle RoM 
in diabetic patients was reported to have a range of 21 - 23.6 degrees, and 24.4 - 
26.7 degrees for controls. Values of the knee RoM were reported to have a range of 
25.5 - 54.3 degrees for the DPN group and 30.7 - 57.7 degrees for the Ctrl group. 
Hip RoM for the DPN group was reported to have a range of 38.9 - 43.2 degrees for 
the DPN group and 40.5 - 44.7 for the Ctrl group (1, 50, 87, 95, 110, 123). The 
reported values for the range of joint movement (i.e., the minimum to maximum joint 
movement) were higher at the hip for diabetic patients compared to controls, but 
lower at the ankle with more variation in range reported at the knee in diabetic 
patients. 
1.7.3 Kinetics of gait 
The ground reaction forces (GRF) have been investigated both in diabetes and 
controls patients. It was anticipated that DPN patients would exhibit higher GRF due 
to neurological deficit and reduced proprioception, causing a relatively higher impact 
with the ground. Constantly higher values of the GRFs have been reported in the 
diabetes patients compared to controls (129, 142, 125, 159) with the values at initial 
contact in the range of 82.5 and 104 N/BW% for the diabetes patients and 80-91.2 
N/BW% for the control group. Sacco et al. (123) were the only group who 
differentiated the two peaks of the GRF, the first at heel strike and another at the 
moment of propulsion. For the first peak, they agreed with Katoulis et al. (73) and 
Uccioli et al. (142) who did not find a difference in the mean GRFs between controls 
and patients with or without neuropathy. Concerning the second peak, however, they 
found a significant difference between vertical forces of controls and the values of 
the diabetic group. In addition to patients with and without neuropathy, Katoulis et 
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al. (73) evaluated a group of diabetes patients with previous ulcers. They described 
a decrease in the maximum value of the vertical component of the GRF for these 
patients compared to healthy controls, and diabetic patients without neuropathy 
(p<0.03). Meier et al. (89) investigated the anterior posterior (A/P) and medio-lateral 
(M/L) forces during stopping tasks. The participants were instructed to walk at their 
self-selected walking speed and to stop in front of the marked stopping line on the 
walkway. They found a slower A/P speed of the centre of mass (CoM), and larger 
A/P and M/L centre of pressure overshoots than in controls. Furthermore, they 
described decreased shock absorption at heel strike and Uccioli et al. (142) 
described significantly reduced peak forces recorded mainly during heel strike and 
push-off for patients with diabetes compared to a control group. During walking, 
movement is caused by moments of force generated by muscles around ankle, knee 
and hip joints. Joint moments are a measure of the rotational force acting around a 
joint, allowing an indication of the magnitude of the muscle force and they have been 
well investigated both in diabetic and non-diabetic populations. Similar findings have 
been reported across a range of studies (21, 128, 76, 95, 96, 159) where patients 
with diabetes are reported as developing lower ankle joint moments during walking. 
The knee joint extension moment tended to be lower in DPN participants. In a study 
that did not control gait velocity, Kwon et al. (76) found similar results comparing 
subjects with and without DPN, but in addition they reported decreased maximal 
plantarflexion moments and knee joint extension moments Mueller et al. (95) found 
reduced maximal plantarflexion moments in diabetic polyneuropathy. Katoulis et al. 
(73) described lower knee joint moments in the DPN group compared to controls. 
They also notice that gait alterations in people with diabetes and neuropathy could 
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facilitate foot injuries, thus contributing to frequent foot ulceration. As the main cause 
for lower moments all authors suggested that this alteration might be caused by a 
decline in plantarflexor strength and slower self-selected walking speed in people 
with neuropathy. External and internal moment arms are important measurements 
contributing to the calculation of the effective mechanical advantage around a joint. 
The external moment arm (ExtMA) length around the ankle during walking is defined 
as the perpendicular distance between the resultant GRF vector in sagittal plane and 
the ankle joint centre of rotation. A smaller ExtMA at the ankle means that either the 
resultant GRF is applied closer to the ankle joint centre or the angle of application is 
more towards the ankle, making the ExtMA smaller, thereby minimising the ankle 
joint moment (assuming a similar GRF). The effective mechanical advantage around 
the ankle is given by the ratio of the internal (Achilles tendon moment arm) to the 
ExtMA, with lower values reflecting a relatively greater contribution from the 
plantarflexor muscles towards the joint moment required to overcome the external 
resistance applied (15). Indeed, it has been shown in a healthy population how a 
marked increase in the ExtMA around the knee and therefore a marked reduction in 
the effective mechanical advantage at the knee, likely accounts for the marked 
increase in the cost of transport when going from walking to running (14). To the best 
of our knowledge there are no previous studies reporting the effective mechanical 
advantage in diabetes patients during walking, but it has been measured for different 
human and animal populations (10, 14, 54, 130, 136). 
1.7.4 Muscle activity during gait 
Neuropathic damage of the nerves affects motor control of the lower limbs, as DPN 
affects proprioception of lower limb position. Patients with DPN display a decreased 
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nerve conduction velocity, and impaired contractile properties as a result of non-
enzymatic glycation, which in tandem results in a slower muscle response (65, 90, 
124). During locomotion, patients with DPN exhibit delayed peak muscle activations, 
despite an earlier activation of muscles, which may lead to decreased motor control 
during walking (57). Handsaker et al. (57) observed the delayed activation during 
stair ascent of the knee extensors and plantarflexors in patients with diabetic 
neuropathy. These delayed activations may explain a slower speed of strength 
generation in the knee and ankle extensors of the DPN group. During stair descent, 
changes are observed in the plantarflexors with a significantly earlier activation, a 
longer time to peak activation, and longer duration of activation. Persons suffering 
from diabetes used nearly twice the muscular activity compared to controls to initiate 
and maintain gait at a lower walking speed. The earlier activation of the 
plantarflexors in patients with DPN is expected to be an anticipatory mechanism, 
preparing the ankle joint to stabilize before contact with the step actually occurs 
(Kwon et al., 2003; Sacco et al., 2000). It has been well documented significantly 
earlier activation of the gastrocnemius medialis, lateralis, soleus, tibialis anterior, 
vastus lateralis, and biceps femoris muscles in DPN patients, in addition to a 
prolonged cessation times of tibialis anterior and vastus medialis muscles (41, 2, 4, 
50, 76, 124, 129). 
1.7.5 Centre of mass vertical displacement during gait 
Large vertical centre of mass displacement (CoM) results in increasing in the 
metabolic cost of walking, because of greater mechanical work performed at the 
ankle, knee and hip joints (52). It has been suggested by Chwala et al. (29) that the 
main element of biomechanical cost of walking is energy used to control the 
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displacements of the CoM. Kinematic methods are predominantly used to determine 
the vertical displacements of the CoM during a gait cycle (40). Race walking events 
can be used as an example of how the CoM influences the metabolic CoW, where 
the speeds must be significantly higher, slightly above the threshold speed, but then 
the gait becomes more “costly”. To minimise the CoW individuals movement should 
be optimised towards minimal vertical oscillations of the centre of mass combined 
with a smooth passage from the heel-strike to toe-off phase involving only small 
changes in kinetic energy. 
 
1.8 Tendon properties in people with Diabetes mellitus 
Muscles attach to the skeleton via tendons. Tendons are force transmitters enabling 
skeletal movement. They are structural links between muscles and bones (114, 161, 
24) and they transfer forces to the skeleton and the environment. Tendons are 
mechanically responsible for transmitting muscle forces to bone, and in doing so, 
permit locomotion and enhance joint stability (70). Tendons are spring-like structures 
and they respond by increasing their mechanical stiffness in response to chronic 
loading and decreasing with chronic unloading (102). Tendons consist of a 
collagenous matrix and demonstrate viscoelastic properties. This property enables 
forces to transmit (75), store and return elastic strain energy during locomotion and 
other movements (55, 47). The muscle-tendon complex has a very important role in 
gait mechanics of humans. The tendon is not an inert structure; both muscles and 
tendons are highly malleable tissues (32) and just as skeletal muscle displays 
plasticity to changes in the level of physiological loading. The function of tendons 
can be classified into two categories: tensile force transmission, storage and release 
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of elastic strain energy during locomotion (81). Tendons of both animals (23, 154, 
155) and humans have been shown to respond to loading levels higher than those 
experienced habitually (running in animals and resistive training in humans), by 
increasing their tensile stiffness (115). Animal studies show that diabetes affects 
non-enzymatic glycation of soft tissues, such as tendon (113). This causes increased 
cross-linking, increasing the stiffness and modulus of the tendon (111, 112). 
Furthermore, tendon tensile stiffness is increased, limiting the range of joint motion 
at the ankle and knee (31, 87). In humans, calcification and fascicle disruption have 
been observed in the diabetic human Achilles tendon (13). Stiffening of the tendon 
will reduce the degree to which it can be stretched, affecting its potential for storing 
elastic strain energy during walking. The Achilles tendon is particularly important for 
storing and releasing elastic energy during walking (6) and can lead to the significant 
metabolic energy savings, as it actually ‘spares’ the muscle from performing a large 
part of the work. Since tendons exhibit low mechanical hysteresis, most of the elastic 
energy stored during stretching is returned on recoil (82). Thickness and stiffness of 
plantar fascia (the flat band of tissue (ligament) that connects calcaneus to toes) and 
Achilles tendon are increased in type I and type II diabetic subjects, mainly in those 
with peripheral neuropathy (1). In patients with diabetes however, it is hypothesised 
that this energy saving mechanism of the Achilles tendon will play a far less-
significant role during walking compared to healthy matched-controls. As a result, it 
is hypothesised that the plantarflexor muscles will need to contribute a relatively 
greater proportion of the energy required, thereby increasing the energy cost of 
walking for diabetic patients compared to matched-controls. Cronin et al. (31) found 
the Achilles tendon length changes to be attenuated in the DM patients and that they 
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were inversely correlated with diabetes duration, as was the ankle range of motion. 
Also, they found that tendon length changes were independent of walking speed and 
age in the diabetic group. 
 
1.9 The Metabolic Cost of walking 
A parameter that characterizes locomotion is the metabolic cost of walking (CoW) 
and is defined as the energetic cost needed to travel a given of distance. Of particular 
interests are several studies that examined the CoW in different cohorts and different 
conditions. Houdijk et al. (61) found that the effort for balance control can elicit a 
meaningful metabolic energy demand. The same authors also found that the 
increased mechanical work for the step-to-step transition from prosthetic to intact 
limb contributes to the increased metabolic energy cost of amputee walking. Van 
Engelen et al. (114) proved that tibiotalar arthrodesis leads to higher metabolic 
energy cost during walking. Energy expenditure of stroke patients has been 
investigated during postural control tasks (63), as well as the treadmill and 
overground walking. The main conclusions are that impaired balance control should 
not be overlooked as a contributing factor to the increased energy cost of walking in 
patients with stroke, and improving or assisting balance control should be considered 
to reduce the energy cost of hemiplegic. They have provided further evidence that 
active control of medio-lateral stability during walking imposes a metabolic demand 
even in young healthy people. IJmker et al. (66) demonstrated that the effect of 
lateral stabilization on energy cost is independent of walking speed, suggesting that 
medio-lateral stability is not influenced by walking speed in young healthy persons. 
The CoW is an important factor that could contribute towards dictating a slower self-
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selected walking speed in diabetes patients. As walking speed increases, joint 
moments and work are expected to increase (39, 152), increasing the CoW. The 
slower self-selected speed may therefore reflect the most efficient strategy for 
diabetes patients as previously shown in other populations (92, 86, 12, 162). The 
CoW is known to be higher in healthy elderly people compared to young adults, 
which likely reflects energetic inefficiencies in older people (92). Knowing some key 
‘inefficiencies’ are present in people with diabetes, it might be expected that the CoW 
would be higher in people with diabetes, but so far this remains unknown. A higher 
CoW in people with diabetes may underpin the lower physical activity levels and 
lower habitual walking distances in this population and may also contribute towards 
a negative spiral where there is a greater perception of difficulty for walking, which 
causes less engagement in physical activity (Maluf et al., 2003; Morrato et al., 2003; 
Tudor-Locke, 2002, 2004), leading to poorer metabolic control and worsening of the 
diabetic condition. To allow intervention to break this negative cycle, it is therefore 
important to understand the factors that contribute to increasing the CoW in diabetes. 
1.10    Thesis aim 
The purpose of this thesis was to investigate the energy cost of walking in people 
with diabetes and examine biomechanical factors that could contribute to explaining 
any potential differences. 
 
1.11 Thesis outline 
This thesis will take the form of six chapters, focusing around the presentation of four 
experimental chapters. The first experimental chapter reports the metabolic cost of 
walking (CoW) in people with diabetes and diabetic peripheral neuropathy across a 
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range of matched walking speeds and gives an insight of the muscle concentric 
work. Experimental chapter 2 investigates the external moment arm and the effective 
mechanical advantage around the ankle during walking across a range of matched 
walking speeds in people with diabetes and diabetic peripheral neuropathy. 
Experimental chapter 3 examines muscle-tendon behaviour during walking for its 
potential role in the CoW in people with diabetes and diabetic peripheral neuropathy. 
The final experimental chapter 4 investigates the vertical displacement of CoM 
during walking across a range of matched walking speeds in people with diabetes 
and diabetic peripheral neuropathy. The last chapter summarises all findings, brings 
conclusions, limitations and possible future work. 
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2. Experimental chapter one - Is the metabolic cost of walking 
higher in people with diabetes? 
 
2.1 ABSTRACT 
People with diabetes walk slower and display biomechanical gait alterations 
compared to controls, but it remains unknown whether the metabolic cost of walking 
(CoW) is elevated. Thirty-one non-diabetic controls (Ctrl); 22 diabetic patients 
without peripheral neuropathy (DM) and 14 patients with moderate/severe DPN, 
underwent gait analysis using a motion analysis system and force plates and 
treadmill walking using gas analyser to measure oxygen uptake. The aim of this 
study was to investigate the CoW and the lower limb concentric joint work as a major 
determinant of the CoW, in patients with diabetes and diabetic peripheral neuropathy 
(DPN). The CoW was significantly higher particularly in the DPN group compared to 
controls and also in the DM group (at selected speeds only) compared to controls, 
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across a range of matched walking speeds. Despite the higher CoW in patients with 
diabetes, concentric lower limb joint work was significantly lower in DM and DPN 
groups compared to controls. The higher CoW is likely due to energetic inefficiencies 
associated with diabetes and DPN reflecting physiological and biomechanical 
characteristics. The lower concentric joint work in patients with diabetes might be a 
consequence of kinematic gait alterations and may represent a natural strategy 
aimed at minimizing the CoW. 
 
 
2.2 INTRODUCTION 
Diabetes mellitus (DM) is a disease with a global reach, the prevalence of which is 
increasing at an alarming rate, with type 2 diabetes being particularly common 
among older adults. The prevalence of diabetes in most developed countries ranges 
between 2.1% (Iceland) and 10.5% Brazil (70, 82, 13). The world health organisation 
estimates that by 2025 as many as 200–300 million people worldwide will have 
developed type 2 diabetes (69). 
Diabetic peripheral neuropathy (DPN) is one of the most common complications 
associated with diabetes occurring in 30–50% of patients and causing dysfunction 
of peripheral nerves (17, 22). Diabetic neuropathy affects sensory, motor and 
autonomic components of the nervous system. In terms of complications arising from 
diabetic neuropathy and impacting upon gait, a loss of sensory perception and 
impaired muscle function are major factors.  
Diabetes patients have consistently been shown to display a slower self-selected 
walking speed, and take shorter strides compared to age-matched controls (19, 46, 
28). Diabetic patients also generate lower knee and ankle joint moments compared 
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to controls during walking (56, 52, 14). It could be suggested that diabetic patients 
walk more slowly at least in part to keep the joint moment demands of gait lower, 
which may therefore explain their lower walking speed. However, lower joint 
moments during gait in diabetic patients have also been shown to be independent 
of walking speed (14).  
The cost of walking (CoW) is another important factor that could contribute towards 
dictating a slower self-selected walking speed in diabetes patients. As walking speed 
increases, joint moments and work are expected to increase (24, 79), increasing the 
CoW. The slower self-selected speed may therefore reflect the most efficient 
strategy for diabetes patients as previously shown in other populations (53, 6, 49, 
84).  
The CoW is known to be higher in healthy elderly people compared to young adults, 
which likely reflects energetic inefficiencies in older people (53). Despite previous 
studies describing gait alterations in people with diabetes, the CoW and its relation 
to walking speed remains unknown in this clinical population. Lower limb concentric 
joint work is closely related to the CoW, with higher joint work being linked to a higher 
CoW (24, 79). Knee and ankle concentric joint work has recently been shown to be 
lower in people with diabetes during walking at a self-selected speed compared to 
controls (14), which might suggest a lower CoW as a result. However, there are also 
a number of energetic inefficiencies present in patients with diabetes that might 
increase the CoW for any given speed. For example, the effects of non-enzymatic 
glycation has been shown to stiffen tendons in animal models of diabetes (30, 58, 
61, 62, 63). A stiffer Achilles tendon may reduce the amount of elastic energy stored 
in the tendon during walking (based upon the assumption of lower forces and 
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therefore smaller elongations resulting from the lower joint moments developed in 
diabetic patients compared to controls). Reduced elastic energy storage in the 
Achilles tendon would increase the amount of energy required from ankle muscles, 
thereby increasing the CoW. Other factors that could contribute to energetic 
inefficiencies during walking in diabetic patients include altered leverage around the 
foot due to diabetic foot deformities and increased antagonist muscle co-activation 
(80, 19, 33).  
The aim of this study was therefore to investigate the CoW (and the lower limb joint 
work as a major determinant of the CoW) in patients with diabetes and diabetic 
neuropathy compared to controls at a range of matched walking speeds. I 
hypothesised that due to the above-mentioned inefficiencies in diabetes patients, 
they would display a higher CoW when walking at the same speed compared to 
controls and that this would be more marked in diabetes patients with DPN 
compared to those without. 
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2.3 MATERIALS AND METHODS 
Participants 
After receiving ethical approval from all relevant bodies, a total of sixty seven 
participants gave written informed consent to participate in this study. All procedures 
in this study complied with the declaration of Helsinki. All participants were aged over 
40 years and were allocated into one of three groups: healthy controls without 
diabetes or peripheral neuropathy (Ctrl, n=31, 19 men), patients with diabetes but 
no neuropathy (DM, n=22, 12 men) and patients with diabetes and moderate-severe 
peripheral neuropathy (DPN, n=14, 14 men). All participants were assessed to 
confirm they satisfied the inclusion criteria for each group. Exclusion criteria for 
participation in the study were vascular disease, unstable ischemic heart, 
neurological, rheumatic disease, cerebral injury, disorders of the vestibular system, 
musculoskeletal injury, recent surgery affecting gait, foot or lower limb amputation 
(amputation of the hallux; amputation of more than two lesser toes on one foot; 
amputation of part of/whole foot) and open foot ulcer. Information about duration and 
type of diabetes, smoking habits and use of current medication was obtained via 
questionnaire. The majority of the DM and the DPN patients reported taking insulin, 
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cholesterol-lowering medication and diabetes medication, while from the whole 
sample (including controls) only 2 people reported smoking. Participant 
characteristics are displayed in Table 3. 
 
Assessment of peripheral neuropathy 
A clinical evaluation was undertaken to quantify neuropathy in diabetic patients and 
to confirm the absence of neuropathy in healthy controls. Peripheral neuropathy was 
assessed by using the modified Neuropathy Disability Score (mNDS) and the 
vibration perception threshold (VPT). The mNDS is a combined score taken from 
tests measuring the patient’s ability to detect temperature, pain, vibration and the 
Achilles tendon reflex (10). The VPT was assessed by placing the probe of the 
biothesiometer on the apex of the hallux and increasing the level of vibration until 
detected by the participant. A random blood glucose test was performed in the Ctrl 
group to confirm the absence of diabetes and the above neuropathy tests conducted 
to confirm the absence of neuropathy in the Ctrl group resulting from any aetiology. 
 
Modified Plug-in-gait based marker set  
A full-body Plug- In-Gait marker set (Vicon®, 2002) was selected due to the minimal 
number of markers required for a full-body model. The plug-in-gait model uses joint 
calibration markers for both segment definition and tracking, thereby minimising the 
need for additional tracking markers. Whilst the model employed for the studies 
within this thesis include additional tracking markers, the intention of these markers 
is to provide additional redundancy in the model rather than to replace the calibration 
markers. The plug-in-gait model has previously been shown to have good 
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repeatability, and good comparability to other models including a six-degrees of 
freedom approach for sagittal plane motion. Some markers have fewer placement 
constraints still; these are tracking markers only and are not used for defining the 
body segment; rather during the model’s calibration their position is calculated 
relative to the segment in order to define it’s position during gait, these markers then 
provide more reliable tracking of the segments during the trials. 
 Figure 1. Marker placements in anterior, posterior and lateral views. 
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Table 1. Upper body marker placements (head, arms and torso). 
Marker Landmark/Placement 
1. Head 1 Headband: left front 
2. Head 2 Headband: right front 
3. Head 3 Headband: left back 
4. Head 4 Headband: right back 
5. Right Shoulder Acromio-clavicular joint (right) 
6. Left Shoulder Acromio-clavicular joint (right) 
7. Cervical 7 7th cervical vertebra 
8. Thorax 10 10th Thoracic vertebra 
9. Sternum Xiphoid process 
10. Scapula Inferior angle 
11. Clavicula Incisura jugularis 
12. Left Upper Arm 
On upper arm between Elbow and Shoulder 
(Left) 
13. Left Elbow Lateral epicondyle (Left) 
14. Left Wrist Medialis Styloid process of Radious (Left) 
15. Left Wrist Lateralis Styloid process of Ulna (Left) 
16. Left Finger 
On the hand just proximal to the 2nd metacarpal 
head (Left) 
17. Right Upper Arm 
On upper arm between Elbow and Shoulder 
(Right) 
18. Right Elbow Lateral epicondyle (Right) 
19. Right Wrist 
Medialis 
Styloid process of Radious (Right) 
20. Right Wrist 
Lateralis 
Styloid process of Ulna (Right) 
21. Right Finger 
On the hand just proximal to the 2nd metacarpal 
head (Right) 
 
Table 2. Lower body marker placements (pelvis and legs). 
 
22. Left SISA Left anterior superior iliac spine 
23. Right SISA Right anterior superior iliac spine 
24. Sacrum 1 Left posterior superior iliac spine 
25. Sacrum 2 Right posterior superior iliac spine 
26. Sacrum 3 
Placed midway between Sacrum 1 and 
Sacrum 2 markers and slightly inferior 
27. Left Upper Thigh 
On the lateral side of the left thigh, 
approximately halfway between hip centre 
and knee centre. It should be aligned 
anteroposterially with the knee and hip 
extension/flexion axes 
28. Right Upper Thigh 
On the lateral side of the right thigh, 
approximately halfway between hip centre 
and knee centre. It should be aligned 
anteroposterially with the knee and hip 
extension/flexion axes 
29. Left Knee Lateral 
Lateral femoral epicondyle (Left leg) – lateral 
side of knee flexion/extension axis 
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30. Right Knee Lateral 
Lateral femoral epicondyle (Right leg) – 
lateral side of knee flexion/extension axis 
31. Left Knee Medial 
Medial femoral epicondyle (Left leg) medial 
mirror of Left Knee Lateral marker so that the 
line connecting the two markers 
approximates the flexion/extension joint axis. 
32. Right Knee Medial 
Medial femoral epicondyle (Right leg) medial 
mirror of Right Knee Lateral marker so that 
the line connecting the two markers 
approximates the flexion/extension joint axis. 
33. Left Shank 1 
Top 1/3 of shank, in the same plane as the 
knee and ankle flexion/extension axes (Left 
leg) 
34. Left Shank 2 
Bottom 1/3 of shank, in the same plane as the 
knee and ankle flexion/extension axes (Left 
leg) 
35. Left Shank 3 
Placed midway between Left Shank 1 and 
Left Shank 2 markers and slightly inferior 
36. Right Shank 1 
Top 1/3 of shank, in the same plane as the 
knee and ankle flexion/extension axes (Right 
leg) 
37. Right Shank 2 
Bottom 1/3 of shank, in the same plane as the 
knee and ankle flexion/extension axes (Right 
leg) 
38. Right Shank 3 
Placed midway between Right Shank 1 and 
Right Shank 2 markers and slightly inferior 
39. LANKMED Medial malleolus (Left ankle) 
40. RANKMED Medial malleolus (Right ankle) 
41. LANKLAT Lateral malleolus (Left ankle) 
42. RANKLAT Lateral malleolus (Right ankle) 
43. LHEEL On the left calcaneus 
44. RHEEL On the right calcaneus 
45. Left B1 Base of the first metatarsal bone (Left foot) 
46. Left H1 Head of the fifth metatarsal bone (Left foot) 
47. Left B5 Base of the first metatarsal bone (Left foot) 
48. Left H5 Head of the fifth metatarsal bone (Left foot) 
49. Right B1 Base of the first metatarsal bone (Right foot) 
50. Right H1 Head of the fifth metatarsal bone (Right foot) 
51. Right B5 Base of the first metatarsal bone (Right foot) 
52. Right H5 Head of the fifth metatarsal bone (Right foot) 
53. Left Toe Tip of left toe 
54. Right Toe Tip of right toe 
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Figure 2. Fully labelled standing calibration file in Nexus (Vicon, Oxford, UK). 
 
Gait analysis 
Participants were asked to walk along a 10-metre walkway in the gait laboratory. 
Participants were instructed to walk the length of the walkway at a series of 
different walking speeds performed in a specific order (0.6, 0.8, 1.0, 1.2, 1.4 and 
1.6 m/s). Walking speed was controlled by measuring the velocity of a marker 
attached to the sacrum after each trial from the motion analysis data and 
providing immediate feedback for participants as to whether they needed to walk 
more quickly or more slowly on the next trial to achieve the required speed, 
allowing +/- 5% deviation from the required speed. Participant's starting position 
was altered by the experimenters to ensure a ‘clean’ (i.e., no overlap outside the 
force platform) foot-strike on one or two of the force platforms per walking trial 
without alteration to their natural gait. Walking trials were repeated until at least 
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three ‘clean’ foot contacts with the force platforms were made per limb, per speed 
condition. Kinematics were collected at 100 Hz using a full-body modified Plug-
In-Gait marker set with 54 markers and a 10-camera Vicon motion capture 
system (Vicon, Oxford, UK) positioned around the 10-meter walkway. Kinetics 
were simultaneously collected at 1000 Hz from three force platforms (Kistler, 
Zurich, Switzerland) embedded into the middle of the walkway. Where possible 
markers were placed directly onto the skin; to minimise movement artefacts 
resulting from loose clothing all participants wore tight-fitting shorts and tops. All 
participants wore specialist diabetic shoes (MedSurg, Darco, Raisting, Germany) 
with a neutral foot-bed, ensuring the diabetic patients walked with safe, 
appropriate footwear whilst minimising the effect of footwear by standardising 
across all participants. 
 
Oxygen uptake measurements and metabolic calculations 
Prior to testing, all participants completed walking familiarisation sessions for a 
minimum of 6 minutes on the treadmill to become accustomed to the task of 
treadmill walking and enable a natural walking style to be achieved. 
Measurements of expired air were acquired whilst participants walked on a motor-
driven treadmill (Woodway Ergo ELG 70, Weil am Rhein, Germany) set at six 
different walking velocities (0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 m/s). The treadmill was 
inclined by 1% from horizontal for the purpose of increasing the similarity of 
oxygen uptake demands with level ground walking as previously shown (34, 38). 
Participants wore a facemask, which passed expired air into an automated 
analyser (Cortex Metalyser 3B, Biophysik, Leipzig, Germany). The analyser, 
calibrated prior to each testing session, provided breath-by-breath data sent via 
telemetry to a computer. Oxygen consumption (VO2) was measured continuously 
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using this online system. The net VO2 during walking was determined as: 
Net VO2 = gross VO2 - resting VO2× 
×resting VO2 was measured during quiet standing on the treadmill prior to walking. 
  
Net VO2 was expressed relative to body mass for all participants. The cost of 
walking was calculated using the mean rate of oxygen consumption for VO2 data 
collected between the 3rd and 4th minute of each stage. 
Net VO2 was converted to joules using an energetic equivalent and calculated 
using the specific respiratory exchange ratio (RER) value from each participant 
as (29): VO2 • (4.94 • RER + 16.04). The CoW was calculated by dividing VO2 by 
the walking speed and multiplying this value for the energy equivalent. Using the 
RER and calculating the energetic equivalent in this way takes into account 
possible differences between groups due to the contribution of the anaerobic 
energy system. Nine participants (Ctrl=3, DM=1, DPN=5) were unable to walk for 
a sufficient period of time at 1.6 m/s to derive adequate VO2 measurements at 
this specific speed. 
 
Gait biomechanical analysis 
Temporal–spatial parameters (walking speed, stance time) were calculated from 
the gait analysis testing session described above using Visual 3D software (C-
motion Inc., MD, USA), using the process of inverse dynamics to calculate joint 
powers. Power curves during stance were calculated to assess concentric 
(positive) periods of power during the stance phase to calculate concentric joint 
work done, defined as the positive power-time integral (14). Concentric joint work 
done was then subsequently normalised to body mass. Work done (ankle, knee, 
and hip) was calculated taking into account data from both legs, across at least 
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three trials (data from at least six stance phases). 
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to 
assess between group differences. If the ANOVA was significant, a Fisher’s least 
significant difference (LSD) post-hoc test was used to test for differences between 
the diabetes groups (DM and DPN) and the control group. All values presented 
are means and standard deviation. All statistical tests were performed on SPSS 
statistical package (SPSS v21, Chicago, Illinois) with significance set at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 RESULTS 
Participant characteristics  
There were significant differences between the groups in age, body mass and 
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BMI, which were significantly greater in the DPN group (Table 3, p<0.01).  
 
Neuropathy assessments  
As expected, the DPN group displayed significantly higher values for the VPT 
and the mNDS compared to the Ctrl group (Table 3). The VPT and mNDS for the 
DM group were not significantly different from the Ctrl, underlining that this 
diabetic patient group had no neuropathy (Table 3). 
 
Temporal–spatial gait parameters  
The DPN group displayed significantly longer single limb stance times and shorter 
step lengths in all given speeds compared to Ctrl group (Table 4). 
 
Total joint work during walking at different speeds 
Total concentric work showed a very consistent pattern across all speeds with 
the Ctrl group displaying the highest values, followed by lower values in the DM 
group and the lowest values observed in the DPN group (Fig. 3). Compared to 
the Ctrl group, significantly lower joint work was observed at all speeds for the 
DPN group and all but 1.4 m/s for the DM group.   
 
Ankle, knee and hip joint work during walking  
Ankle concentric joint work was lower for the DPN group compared to the Ctrl 
group, reaching significance at gait velocities of 0.8; 1.2; 1.4 and 1.6 m/s (Fig. 3). 
Knee concentric joint work was significantly lower in the DPN group compared to 
Ctrl at gait velocities of 0.6; 0.8; 1.0; 1.2 and 1.6 m/s. In the DM group, knee 
concentric joint work was significantly lower compared to Ctrl at the gait velocity 
of 0.6 m/s. Hip concentric joint work was lower for the DPN group compared to 
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Ctrl reaching significance at velocities of 0.6; 0.8 and 1.6 m/s. 
 
Cost of walking at different speeds 
There were significant differences in the CoW between the groups across the 
matched speeds tested, with the general pattern of a higher CoW in the DPN 
group, followed by the DM group and the lowest CoW in the Ctrl group (Table 4; 
Fig. 4). Significant differences in the CoW were mainly found between the DPN 
and Ctrl groups (at 0.6; 0.8; 1.0; 1.2 and 1.6 m/s), with some significant 
differences also present between DM and Ctrl groups at the higher gait velocities 
(1.4 and 1.6 m/s). 
 
 
Table 3. Participant characteristics and results from neuropathy assessments. 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 56 (10) 51 (9)** 66 (14)** 
Body mass (kg) 76 (10) 80.5 (12) 91.5 (18)** 
Height (m) 1.72 (0.12) 1.71 (0.09) 1.73 (0.11) 
BMI (kg/m2) 26 (3) 28 (4) 31 (4)** 
NDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3.4) 8.2 (3.4) 27.4 (9.1)** 
Diabetes duration (years) - 14 (12) 14 (11) 
Type 1 diabetes - 7 4 
Type 2 diabetes - 15 10 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) 
and diabetic patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by *(P<0.05) or ** (P<0.01). BMI = 
body mass index, NDS = neuropathy disability score, VPT = vibration perception 
threshold. Values are means (standard deviations). 
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Figure 3. Lower limb ankle, knee, hip and total concentric joint work across 
walking speeds from 0.6 to 1.6 m/s for healthy controls (Ctrl, n=31), diabetic 
patients with no neuropathy (DM, n=22) and diabetic patients with 
moderate/severe neuropathy (DPN, n=14). Values are group means and SD, 
**denotes significantly (P<0.01) different from the control group. 
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Figure 4. The cost of walking (CoW) plotted across walking speeds from 0.6 to 
1.6 m/s for healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, 
n=22) and diabetic patients with moderate/severe neuropathy (DPN, n=14). Nine 
participants (Ctrl=3, DM=1, DPN=5) were unable to walk for long enough to 
calculate the CoW at 1.6 m/s. Values are group means and SD, **denotes 
significantly (P<0.01) different from the control group. 
 
 
 
Figure 5. Mean data for the cost of walking (CoW) plotted against total concentric 
work during walking at walking speeds from 0.6 to 1.6 m/s for healthy controls 
(Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and diabetic 
patients with moderate/severe neuropathy (DPN, n=14). The curves were fitted 
with a cubic function to yield R2 values over 0.98. Line graphs: Ctrl - solid line, 
DM - dotted line, DPN - dashed line. 
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Table 4. Temporal-spatial gait parameters and net oxygen uptake.  
    Variable Group 
 Ctrl DM DPN 
0.6 m/s 
Actual speed (m/s) 
 
0.57 (0.24) 
 
0.59 (0.16) 
 
0.61(0.11) 
Step length (m) 
Single limb stance time (sec) 
0.59 (0.20) 
0.902 (0.20) 
0.57 (0.24) 
0.841(0.23) 
0.51 (0.09)** 
0.958 (0.05)** 
Net VO2 (ml/min kg) 3.81 (1.11) 3.05 (1.69) 4.93 (2.95)** 
RER 0.89 (0.05) 0.93 (0.08) 0.96 (0.09) 
0.8 m/s    
Actual speed (m/s) 0.82 (0.27) 0.78 (0.21) 0.77 (0.19) 
Step length (m) 
Single limb stance time (sec) 
0.63 (0.21) 
0.801 (0.15) 
0.57 (0.21) 
0.842 (0.21) 
0.53 (0.05)** 
0.960 (0.05)** 
Net VO2 (ml/min kg) 5.11 (0.89) 5.00 (1.55) 6.56 (2.94)** 
RER 0.86 (0.09) 0.87 (0.11) 0.97 (0.07) 
1.0 m/s 
Actual speed (m/s) 
 
1.02 (0.17) 
 
1.04 (0.28) 
 
0.97 (0.13) 
Step length (m) 
Single limb stance time (sec) 
0.69 (0.15) 
0.713 (0.13) 
0.67 (0.05) 
0.741 (0.05) 
0.64 (0.04)* 
0.884 (0.05)* 
Net VO2 (ml/min kg) 6.44 (1.08) 6.89 (1.32) 7.75 (3.29)** 
RER 0.84 (0.04) 0.91 (0.06) 0.93 (0.03) 
1.2 m/s    
Actual speed (m/s) 1.18 (0.16) 1.22 (0.15) 1.22 (0.23) 
Step length (m) 
Single limb stance time (sec) 
0.76 (0.11) 
0.579 (0.31) 
0.75 (0.17) 
0.617 (0.05) 
0.69 (0.07)* 
0.682 (0.06)* 
Net VO2 (ml/min kg) 7.46 (1.15) 7.89 (1.29) 8.62 (2.65)** 
RER 0.87 (0.08) 0.91 (0.04) 0.91 (0.07) 
1.4 m/s    
Actual speed (m/s) 1.45 (0.19) 1.44 (0.12) 1.46 (0.19) 
Step length (m) 
Single limb stance time (sec) 
0.79 (0.12) 
0.555 (0.15) 
0.77 (0.17) 
0.579 (0.21) 
0.71 (0.11)* 
0.621 (0.14)* 
Net VO2 (ml/min kg) 9.22 (1.69) 10.73 (0.80)** 9.87 (2.89) 
RER 0.90 (0.07) 0.89 (0.05) 0.93 (0.06) 
1.6 m/s    
Actual speed (m/s) 1.62 (0.27) 1.57 (0.17) 1.59 (0.12) 
Step length (m) 
Single limb stance time (sec) 
0.81 (0.11) 
0.499 (0.15) 
0.80 (0.04) 
0.498 (0.11) 
0.74 (0.02)* 
0.525 (0.01)* 
Net VO2 (ml/min kg) 10.97 (4.45) 12.84 (3.35)** 12.19 (4.99)** 
RER 0.89 (0.04) 0.90 (0.07) 0.98 (0.06) 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) 
and diabetic patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by *(P<0.05) or **(P<0.01). Values 
are means (standard deviations). Gait parameters were collected on the 
laboratory walkway. 
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2.5 DISCUSSION 
This study has shown for the first time that when walking speed is matched, 
patients with diabetic neuropathy have a higher CoW compared to controls (Fig. 
4). Despite a higher CoW, patients with diabetic neuropathy showed significantly 
reduced concentric lower limb joint work compared to controls at these matched 
speeds. The finding of lower joint work in patients with diabetic neuropathy is 
surprising considering that under ‘normal’ conditions lower concentric work is 
clearly linked to a lower CoW (67, 57), but I suggest possible reasons for this 
below.  
The finding of a higher CoW in patients with diabetic neuropathy when walking 
speed was matched likely reflects energetic inefficiencies resulting from a 
number of physiological and biomechanical factors. Firstly, animal models of 
diabetes have shown that tendons are stiffer due to the effects of non-enzymatic 
glycation. In human diabetic patients, this likely applies to the long Achilles 
tendon, which plays a major role in energy saving during walking under ‘normal’ 
circumstances (3). Stiffening of the Achilles tendon with diabetes and especially 
diabetic neuropathy (presumably due to longer exposure with poor glycaemic 
control), would reduce the extensibility of the tendon. Based upon the lower joint 
moments developed in patients with diabetic neuropathy during gait (46, 52, 56, 
81), it would be expected that the force on the Achilles tendon would be lower 
compared to controls. The stiffer Achilles tendon of patients with diabetic 
neuropathy would be expected to elongate less compared to controls, storing less 
elastic energy and requiring more energy to be generated by the plantarflexor 
muscles (assuming similar hysteresis compared to controls), thereby contributing 
to a higher CoW in diabetes patients.  
Higher levels of muscle co-activation during walking have been reported in 
61 
 
diabetic patients compared to controls (1, 32). Considering that locomotion 
should reflect a fine balance between activation and de-activation of agonist and 
antagonist muscles during specific phases of the gait cycle, an increase in the 
level of muscle co-activation will increase metabolic energy cost and could 
therefore be another factor contributing to increase the CoW at a given speed in 
patients with DPN. Foot deformities are common in diabetic patients (29, 78) and 
even subtle changes in foot structure would alter the application of force to the 
ground during walking (43, 51). Changes in the application of force to the ground 
during walking (and running) will alter the mechanical leverage around the ankle 
joint, i.e., the external moment arm. This has been shown both in humans and 
animals (7, 8, 9, 5, 41, 42, 68, 12) and therefore such changes may increase the 
CoW in patients with DPN. Another contributing factor to the higher CoW in the 
DPN group is the increased step frequency (the DPN group had a shorter step 
length for a given speed, therefore requiring a higher step frequency) and greater 
body mass compared to the DM and the Ctrl groups. These two factors 
(increased step frequency and greater body mass) would increase the internal 
work required for moving the lower limbs and may contribute to a higher CoW in 
people with diabetes and particularly those with DPN (54). 
A higher CoW was clearly evident in patients with diabetes (DM group) and 
particularly in those with diabetic neuropathy (DPN group) across the matched 
walking speeds. In this study I examined a range of different walking speeds (from 
0.6 until 1.6 m/s) and observed that the differences in the CoW between groups 
were most evident at the lower gait velocities (0.6-1.2 m/s; Fig. 4). At the higher 
walking speeds, the pattern changes slightly with the CoW still remaining higher 
in patients with diabetes and diabetic neuropathy compared to controls, but with 
the differences being less evident than at the slower walking speeds. This may 
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be explained by patients with diabetic neuropathy moving closer towards their 
maximal oxygen uptake when walking at velocities of 1.4 m/s and above. It is well 
known that diabetes patients engage in less physical activity (48, 55, 72, 73) and 
are therefore likely less fit i.e., have a lower maximal oxygen uptake compared to 
non-diabetic controls (40, 65, 66). It is also a possibility that diabetes patients 
might have reached the lactate threshold earlier than controls (i.e., at lower 
walking speeds), which could have influenced the VO2 kinetics and the time to 
reach a relatively constant VO2. Specifically, with heavy exercise above the 
lactate threshold the VO2 slow component (i.e., the gradual rise in VO2 with 
constant workload) may be more pronounced (77) and there is a risk that diabetes 
patients may have reached their lactate threshold earlier than controls, thereby 
influencing our estimate for the CoW differently between diabetes and control 
participants. Although I did not measure the lactate threshold or the maximal 
oxygen uptake in our participants, previous studies have shown that the lactate 
threshold occurs in other populations at a VO2 between 50 and 55 ml/kg/min, or 
at running speeds of between 3.75 and 4.73 m/s (64, 26, 83, 2). These VO2 
values (50-55 ml/kg/min) and running speeds (3.75-4.73 m/s) are considerably 
higher compared to those measured in our study (VO2 values of up to 13 
ml/kg/min and walking speeds of up to 1.6 m/s; Table 4), and despite these 
previous reports being in healthy populations, it may suggest that all participants 
in the present study were well below their lactate threshold. Future work could be 
conducted to compare the CoW between these groups at relative exercise 
intensities, taking into account individual lactate thresholds. 
The CoW data in the present study are comparable with a number of previous 
studies conducted in similar populations reporting values ranging between 1.1 
and 5 J (kg m)-1 (76, 25, 75, 35, 15, 36, 6, 16, 18, 20, 53, 59). In the DPN group 
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the CoW showed a U-shaped relationship with walking speed as previously 
reported in other populations (53), but this relationship was not as clearly evident 
in the DM and Ctrl groups (Fig. 4). All three groups showed the same consistent 
pattern of increasing net VO2 with increasing walking speed. Slight differences in 
the RER values between groups likely explain the lack of a consistent U-shaped 
relationship between the CoW and walking speed across all three groups. The 
DPN group displayed particularly high standard deviations for the CoW (Fig. 4) 
and VO2 data (Table 4). This high within-group variance is a consistent 
characteristic reported in previous studies with DPN patients for other gait 
variables, but here I also highlight the within-group variance associated with VO2 
and CoW parameters in DPN patients.  
Across the matched walking speeds in the present study, there was a consistent 
pattern of lower total concentric joint work being developed by the DM group and 
particularly the DPN group compared to controls (Fig. 3). A slower walking speed 
is a consistent finding of previous studies in diabetic patients (5, 52, 60, 28). 
Whilst most other studies have examined only self-selected walking speed (45, 
21), the present study is the first to examine a range of different functionally 
relevant matched walking speeds (between 0.6 and 1.6 m/s) in the diabetic 
patient population. Since lower limb joint work is known to be closely linked to the 
CoW, joint work was examined in the present study to provide insight to the 
mechanism(s) for group differences in the CoW. I found a consistent pattern of 
lower joint work in the DM group and particularly in the DPN group compared to 
the Ctrl group for the hip, knee and ankle joints across walking speeds (Fig. 3). 
Theoretically, the same lower limb joint work was associated with a higher CoW 
in diabetic patients and particularly in patients with DPN, which can be observed 
by projecting vertically from any point on the x-axis on Fig. 5.  
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It was surprising that diabetic patients were actually able to match the same 
walking speed as controls despite generating significantly reduced lower limb 
joint work. This interesting aspect might be explained by a number of kinematic 
alterations to gait made by diabetic patients with implications for joint kinetics. 
This may represent an ‘altered gait strategy’ in people with diabetes to enable 
them to meet the task demands in the face of compromised musculoskeletal 
properties and already elevated CoW due to energetic inefficiencies. Diabetic 
patients display a reduced lower limb range of motion during walking compared 
to controls. This is achieved at least in part via shorter steps taken by diabetic 
patients during walking (Table 4). It is known that DM and DPN patients are able 
to lower joint moments and walk with shorter steps and this translates to less 
flexed joints, which in general means that the moment arms of the ground 
reaction force are smaller compared to the situation with more flexed joints. 
Smaller moment arms will lower the joint moments and since joint work is derived 
from the product of joint moments and joint angular speed (joint power), this 
kinematic strategy likely contributes towards reducing the joint work done during 
walking. Concentric contractions are associated with a relatively high metabolic 
load, whereas in contrast, this is much lower for isometric and eccentric 
contractions (27, 23). Despite these strategies to lower the joint moments, 
patients with DPN have a higher CoW presumably due to metabolic inefficiencies 
discussed above. If patients with DPN did not employ these ‘altered gait 
strategies’ presumably the CoW would be even higher.  
There are some limitations in the present study that should be acknowledged. 
Firstly, several participants were not able not complete walking on the treadmill 
at the highest speed (1.6 m/s). Secondly, body mass was significantly different 
between groups, however, this should not affect the two main parameters of the 
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CoW and joint work, since both parameters were normalised for body mass. Also, 
the higher body mass in patients with DPN is a well-known characteristic of this 
population described in the literature (45, 39, 37). Although only a mean of 10 
years difference, patients in the DPN group were significantly older than controls 
(66 to 56 years, respectively), which might be a confounding factor for some of 
the variables examined. I did not measure blood lactate to confirm that all 
participants were working below their lactate threshold. This is a consideration 
since the VO2 slow component is much more pronounced during exercise above 
the lactate threshold compared to below as discussed above. Although the 
intensity of the exercise during walking in the present study was unlikely sufficient 
for participants to exceed their lactate threshold based on comparison with 
previous studies (64, 26, 83, 2), it remains a note of caution since it would affect 
our interpretation of the CoW data if there were between-group differences in the 
onset of the lactate threshold occurring within the range of walking speeds 
examined.    
I have shown that the CoW is higher in patients with diabetes and particularly in 
those with diabetic neuropathy compared to controls when walking speed is 
matched. This higher CoW is likely due to energetic inefficiencies in diabetic 
patients reflecting physiological and biomechanical characteristics and occurs 
despite the development of lower concentric joint work in patients with diabetes 
and diabetic neuropathy. 
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3. Experimental chapter two - Altered leverage around the 
ankle in people with diabetes: a natural strategy to modify 
the muscular contribution during walking? 
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3.1 ABSTRACT 
Diabetes patients display a number of gait alterations compared to controls 
including a higher cost of walking. The aim of this study was to investigate the 
external moment arm (ExtMA) and effective mechanical advantage (EMA) at the 
ankle in patients with diabetes and diabetic peripheral neuropathy compared to 
controls as a potential mechanism contributing to the increased cost of walking. 
Thirty one non-diabetic controls (Ctrl); 22 diabetes patients without peripheral 
neuropathy (DM) and 14 patients with moderate/severe diabetic peripheral 
neuropathy (DPN), underwent gait analysis using a motion analysis system and 
force plates. Internal moment arms were determined using magnetic resonance 
imaging during weight-bearing and external moment arms were calculated using 
gait analysis. A greater value (P<0.01) for the EMA at the ankle joint was found 
in the DPN (0.488) and DM (0.46) groups compared to Ctrl (0.448). This means 
that the ankle plantarflexor muscles develop relatively lower forces to generate a 
given joint moment compared to controls. The increased EMA was mainly caused 
by a smaller external moment arm in the DPN (9.63cm; P<0.01) and DM 
(10.31cm) groups compared to Ctrl (10.42cm). Here, I uncover a new mechanism 
through which patients with diabetes and particularly those with DPN reduce the 
joint moment at the ankle during walking – by applying the ground reaction force 
more proximally on the foot or at an angle directed more towards the ankle, 
increasing the EMA around the ankle and thereby reducing the ankle joint 
moment.  
3.2 INTRODUCTION 
Diabetes presents a global health challenge and the prevalence is increasing 
rapidly, ranging between 2.4% to 24% across various international countries (44, 
48, 7). The world health organisation estimates that by 2025 as many as 200-300 
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million people worldwide will have developed type 2 diabetes (19). One of the 
major complications of diabetes is diabetic peripheral neuropathy (DPN), which 
occurs in 30–50% of patients with diabetes, causing dysfunction of peripheral 
nerves (10, 13). Diabetic peripheral neuropathy affects not only sensory but also 
motor nerves, having implications for movement dysfunction (35, 18, 9). People 
with diabetes walk less and at a slower speed and engage in lower levels of 
physical activity compared to match controls (27, 30, 45, 46). Other gait 
characteristics in diabetic patients include taking shorter strides, spending 
relatively longer in double support (two feet in contact with the ground) and 
generating lower knee and ankle joint moments compared to matched controls 
(31, 11, 22, 9, 12, 14, 24, 29, 31). I have recently shown a higher cost of walking 
(CoW) across a range of matched walking speeds in patients with diabetes and 
especially in those with DPN compared to controls. This higher CoW in people 
with diabetes may underpin the lower physical activity levels and lower habitual 
walking distances in this population and may contribute towards a negative spiral 
where there is a greater perception of difficulty for walking, which causes less 
engagement in physical activity, leading to poorer metabolic control and 
worsening of the diabetic condition. To allow intervention to break this negative 
cycle, it is therefore important to understand the factors that contribute to 
increasing the CoW in diabetes.  
One potential factor that might contribute to increasing the CoW is a greater 
external moment arm (ExtMA) of the resultant ground reaction force (GRF) 
around the ankle, since this will increase the relative contribution from the 
plantarflexor muscles. The effective mechanical advantage (EMA) around the 
ankle is given by the ratio of the internal (Achilles tendon moment arm) to the 
ExtMA, with lower values reflecting a relatively greater contribution from the 
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plantarflexor muscles towards the joint moment required to overcome the 
external resistance applied (5). Indeed, it has been shown in a healthy population 
how a marked increase in the ExtMA around the knee and therefore a marked 
reduction in the EMA at the knee, likely accounts for the marked increase in the 
cost of transport when transitioning from walking to running (4). Although running 
is not an issue of investigation here in diabetes patients, this clearly illustrates the 
concept of how differences in external leverage around joints can impact upon on 
the energy cost of locomotion.  
In diabetes patients the ExtMA at the knee would not be increased since they 
take shorter strides and have less flexed joints compared to controls (31, 11, 22). 
However, many diabetes patients have some level of foot deformity such as a 
high arch, or toe deformities (16, 47), which may result in applying force to the 
ground more distal on the foot, increasing the ExtMA around the ankle, 
decreasing the EMA and thereby increasing the relative contribution from the 
plantarflexor muscles. The EMA around the ankle in diabetic patients could be 
also affected by altered use of the lower limb and foot caused by sensory deficits 
and plantaflexor muscle weakness. A relative increase in the contribution from 
ankle plantarflexor muscles during walking may partly explain the increased CoW 
in diabetes patients and especially those with DPN. 
The aim of this study was to establish whether there are differences in the ExtMA 
and EMA at the ankle in patients with diabetes and DPN compared to controls at 
a range of matched walking speeds, as a potential mechanism contributing to the 
increased CoW recently observed in diabetes patients (32). I hypothesized that 
the ExtMA will be higher and the EMA will be lower in diabetes patients compared 
to controls. 
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3.3 MATERIALS AND METHODS 
Participants 
After receiving ethical approval for the study from all relevant bodies, a total of 
sixty seven participants were recruited, who gave their written informed consent 
to participate. Participants were aged over 40 and allocated into one of three 
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groups based upon defined criteria: patients with diabetes and moderate-severe 
peripheral neuropathy (DPN, n=14, 12 men), patients with diabetes but no 
neuropathy (DM, n=22, 12 men) and healthy controls without diabetes or 
peripheral neuropathy (Ctrl, n=31, 19 men). 
All participants were assessed to confirm they met the inclusion criteria. Major 
exclusion criteria included: severe vascular disease, unstable ischemic heart, 
neurological, rheumatic disease, cerebral injury, disorders of the vestibular 
system, musculoskeletal injury, recent surgery affecting gait, foot or lower limb 
amputation (amputation of the hallux; amputation of more than two lesser toes on 
one foot; amputation of part of/whole foot) and open foot ulcer. A questionnaire 
was used to obtain the following information: duration and type of diabetes, 
smoking habits and use of current medication. The majority of the DM and the 
DPN patients reported taking insulin, cholesterol-lowering medication and 
diabetes medication, while from the whole sample (including controls) only 2 
people reported smoking. Participant characteristics are displayed in Table 1. 
 
Clinical assessment of peripheral neuropathy 
A clinical evaluation was undertaken to quantify neuropathy in diabetes patients 
and to confirm the absence of neuropathy in healthy controls. Peripheral 
neuropathy was assessed by using the modified Neuropathy Disability Score 
(mNDS) and the vibration perception threshold (VPT). The mNDS is a composite 
score taken from tests measuring the patient’s ability to detect temperature 
perception, pain, vibration and the Achilles tendon reflex (6). The VPT is an 
assessment performed using a biothesiometer placed on the apex of the hallux 
and increasing the level of vibration until detected by the participant. A random 
blood glucose test was performed in the Ctrl group to confirm the absence of 
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diabetes and the above neuropathy tests conducted to confirm the absence of 
neuropathy in the Ctrl group resulting from any aetiology. 
 
Gait analysis 
Kinematic data were collected at 100 Hz using a full-body modified Plug-In-Gait 
marker set with 54 markers and a 10-camera Vicon motion capture system 
(Vicon, Oxford, UK) positioned around the 10-meter walkway. Ground reaction 
forces were measured at 1000 Hz synchronously with motion capturing using 
three force platforms (Kistler, Zurich, Switzerland) embedded into the walkway. 
Where possible markers were placed directly onto the skin; to minimise 
movement artefacts resulting from loose clothing all participants wore tight-fitting 
shorts and t-shirts. Participants were instructed to walk the length of the walkway 
at different walking speeds performed in a specific order (0.6, 0.8, 1.0, 1.2, 1.4 
and 1.6 m/s). Walking speed was controlled by measuring the velocity of a marker 
attached to the sacrum after each trial from the motion analysis data and 
providing immediate feedback for participants as to whether they needed to walk 
more quickly or more slowly on the next trial to achieve the required speed. 
Walking trials were repeated until at least three ‘clean’ foot contacts with the force 
platforms were made per limb, per speed condition. All participants wore 
specialist diabetic shoes (MedSurg, Darco, Raisting, Germany) with a neutral 
foot-bed, ensuring the diabetes patients walked with safe, appropriate footwear 
whilst minimising the effect of footwear by standardising across all participant 
groups. 
 
MRI scanning and analysis 
79 
 
Magnetic resonance imaging (MRI) was used to quantify the internal Achilles 
tendon (AT) moment arm length at the ankle as previously described (26). The 
internal moment arm was defined as the perpendicular distance from the centre 
of rotation on the talus to the AT line of action (26). Internal moment arm lengths 
were determined with participants standing upright (i.e., full weight-bearing) in a 
0.25T MRI scanner (E-Scan, Esaote Biomedica, Genoa, Italy). Weight-bearing 
scans were acquired across the predominant range of ankle joint angles (10 
degrees dorsiflexion, neutral position, 10 degrees plantarflexion) experienced 
during walking, to relate these measurements as closely as possible to the 
conditions of walking. In the present study rotation of the ankle joint from 
plantarflexion to dorsiflexion was treated as a single planar mechanism (25, 39, 
41, 38). The ankle joint instant centre of rotation was located following the 
graphical approach described by Reuleaux (37) for ankle angle rotations from 
−10 to 10 deg. Instant centre of rotation was determined by measuring the 
rotation of the talus, which was considered to represent the whole rotating foot, 
relative to the tibia. The AT moment arm was measured on the neutral ankle scan 
as the perpendicular distance from the centre of rotation on the talus to the line 
of action on the AT. All images were analysed using a custom-script written in 
MATLAB software. 
 
 
Measurement of the external moment arm at the ankle during walking and 
foot length 
Foot length was measured in the standing position as the distance between the 
end of the big toe and the heel. The external moment arm (ExtMA) length around 
the ankle during walking was defined as the perpendicular distance between the 
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resultant GRF vector in sagittal plane and the ankle joint centre of rotation. The 
ankle joint centre of rotation was defined from the markers positioned on both 
lateral and medial malleoli. The ExtMA was quantified throughout the stance 
phase on every motion analysis frame from integration of the kinematic data with 
the GRF data.  
 
Calculation of the EMA 
Consistent with the approach used in previous studies (4, 5, 36), the EMA around 
the ankle joint was calculated as the ratio of the internal moment arm length to 
the external moment arm length (Fig. 2).  
 
Effective Mechanical Advantage = 
Internal moment arm
External moment arm
 
 
The ExtMA values were quantified across the stance phase from the kinematic 
data as described above. The internal moment arm values were measured using 
MRI as described above and calculated across the stance phase by using the 
measured ankle joint angle data and the previously reported ratio of internal 
moment arm to ankle joint angle determined from MRI (38). 
 
 
 
Gait biomechanical analysis 
Gait variables were calculated using Visual 3D software (C-motion Inc., MD, 
USA): external moment arm lengths, joint moments, GRFs and ankle, knee and 
hip joint angles. Joint moments and GRFs were normalised to body mass. Data 
for the external moment arms, joint moments and GRFs were collected during 
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the stance phase, while ankle, knee and hip joint ranges of motion (RoM) were 
analysed throughout the gait cycle. Means across both legs and three trials were 
used for all variables presented.  
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to 
assess between group differences. If the ANOVA was significant, a Fisher’s least 
significant difference (LSD) post-hoc test was used to test for differences between 
the diabetes groups (DM and DPN) and the control group. An analysis of 
covariance (ANCOVA) was performed for the external moment arm at peak ankle 
joint moment using foot length as the covariate. All values presented are means 
and standard deviation. Significance was set at p<0.05. 
 
 
 
 
 
 
 
 
 
3.4 RESULTS 
 
Participant characteristics  
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Significant differences existed between the groups in age, body mass and BMI, 
with the DPN group being older and heavier with a greater BMI compared to 
controls (Table 1, P<0.01). 
 
Diabetic Peripheral Neuropathy 
As expected, patients with DPN displayed significantly higher mNDS and VPT 
than the Ctrl and the DM groups (Table 1). There were no differences (P>0.05) 
in the mNDS or VPT between the Ctrl and the DM groups, underlining that this 
diabetes group had no neuropathy. 
 
Temporal–spatial gait parameters  
The DPN group displayed significantly longer single limb stance times and shorter 
step lengths in all given speeds compared to Ctrl group (Table 2). 
 
External moment arm at peak ankle joint moment during walking & gait 
parameters  
The ExtMA length at peak ankle joint moment was significantly smaller (P<0.01) 
in the DPN group compared to the Ctrl group at walking speeds of 0.6; 1.0 and 
1.4 m/s and for the mean across all speeds (Table 2). Significant differences 
(P<0.01) were also observed in the external moment arm length between the DM 
and Ctrl groups at a walking speed of 1.4 m/s. The DPN group displayed 
significantly (P<0.01) longer single limb stance times and shorter step lengths in 
all given speeds compared to the Ctrl group (Table 2). 
Internal moment arm and EMA during walking  
There were no differences in the internal moment arm length in the DPN and the 
DM groups compared to the Ctrl group (P>0.05). The EMA at the ankle was 
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significantly (P<0.01) higher in the DPN group compared to the Ctrl group at 
walking speeds of 0.6; 1.0; 1.2; 1.4, 1.6 m/s and for the mean across all walking 
speeds (Table 2). The EMA at the ankle was also significantly (P<0.01) higher in 
the DM group compared to the Ctrl group at walking speeds of 0.6; 0.8, 1.4 m/s 
and for the mean across all walking speeds (Table 2). 
 
Ground reaction forces during walking  
Ground reaction forces were significantly higher (P<0.01) in the DPN group 
compared to the Ctrl at walking speeds of 0.6; 0.8; 1.0; 1.4 and 1.6 m/s and for 
the mean across all walking speeds (Table 2). Significantly higher (P<0.01) GRF 
values were also found in the DM group compared to the Ctrl group at the walking 
speed of 1.6 m/s and for the mean across all speeds (Table 2). 
 
Peak ankle joint moments & lower limb kinematics during walking 
Peak ankle plantarflexion joint moments were significantly lower (P<0.01) in the 
DPN compared to the Ctrl group for all walking speeds including the mean across 
all speeds (Table 2), with the exception of values at 1.2 m/s. Peak ankle 
plantarflexion joint moments were also significantly lower (P<0.01) in the DM 
compared to the Ctrl group at walking speeds of 1.2, 1.4 and 1.6 m/s and for the 
mean across all speeds (Table 2). 
A significantly (P<0.01) smaller ankle, knee and hip joint RoM was observed in 
the DPN group compared to the Ctrl group across all walking speeds (Table 3). 
Joint RoM was also significantly (P<0.01) reduced in the DM group compared to 
the Ctrl group at the ankle (1.0 and 1.2 m/s), knee (0.8; 1.0; 1.2 m/s and for the 
mean values) and hip (all speeds except 0.6 m/s). Between group differences 
(range of motion) for the DPN and Ctrl groups were in the range 11-15% for the 
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ankle, 4-6% for the knee and 9-11% for the hip across the range of speeds 
examined. Smaller percentage differences were found when the Ctrl group was 
compared to the DM group across the range of speeds (1-5% for the ankle, 1-3% 
for the knee and 4-8% for hip). Smaller ankle RoM in the DPN group was mainly 
brought about through a significantly reduced peak dorsiflexion angle (Table 4). 
Smaller knee RoM was the result of significantly (P<0.01) reduced peak flexion 
and knee extension in the DPN group compared to the Ctrl group (Table 4). 
Despite overall reductions in hip RoM in the DPN compared to Ctrl group (Table 
3), the DPN group displayed significantly (P<0.01) greater hip flexion (Table 4). 
The overall reductions in hip RoM were explained by significantly (P<0.01) 
reduced hip extension in the DPN group compared to Ctrl (Table 4). 
 
 
 
Figure 1. An example sagittal plane MRI scan of the lower limb showing the 
measurement of the internal moment arm length (indicated by the white arrow). 
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Figure 2. Diagram showing the external moment arm length (Ext MA; black 
dashed line) as the perpendicular distance between the resultant GRF vector and 
the joint centre of rotation (●); the internal Achilles tendon moment arm (Int MA; 
red dashed line) as the perpendicular distance between the tendon`s action line 
and the ankle joint centre (●). The EMA is calculated as: IntMA/ExtMA. 
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Figure 3. External moment arm (EMA), ankle joint moment (AJM) and ground 
reaction forces (GRFs) during stance phase while walking at 1.4 m/s for healthy 
controls (Ctrl), diabetic patients with no neuropathy (DM), and diabetic patients 
with moderate/severe neuropathy (DPN). Values are means. Line graphs: Ctrl - 
solid line (n=31), DM - dotted line (n=22), DPN - dashed line (n=14). 
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Table 1. Participant demographics and diabetes characteristics by study group. 
 
 
 
 
 
 
Healthy controls (Ctrl, n=31), diabetes patients with no neuropathy (DM, n=22) 
and diabetes patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by ** (P<0.01). BMI = body mass 
index, mNDS = modified neuropathy disability score, VPT = vibration perception 
threshold. Values are means (standard deviations). 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 56 (10) 51 (9)** 66 (14)** 
Body mass (kg) 76 (10) 80.5 (12) 91.5 (18)** 
Height (m) 1.72 (0.12) 1.71 (0.09) 1.73 (0.11) 
BMI (kg/m2) 26 (3) 28 (4) 31 (4)** 
Foot length (cm) 25.43 (1.76) 24.77 (2.1) 25.81 (2.4) 
Internal MA (cm) 4.72 (0.27) 4.73 (0.30) 4.98 (0.21) 
mNDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3.4) 8.2 (3.4) 27.4 (9.1)** 
Diabetes duration (years) - 14 (12) 14 (11) 
Type 1 diabetes - 7 4 
Type 2 diabetes - 15 10 
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Table 2. Biomechanical parameters at the ankle joint and temporal-spatial parameters during walking at different matched speeds. 
 
 
Healthy controls (Ctrl; n=31), diabetes patients with no neuropathy (DM; n=22) and diabetes patients with moderate/severe neuropathy 
(DPN; n=14). Significant differences from the Ctrl group are denoted by *(P<0.05) or **(P<0.01). Values are means (standard deviations). 
ExtMA @ peak AJM – external moment arm around the ankle at peak ankle joint moment. Peak AJM – peak ankle joint moment. Peak 
GRF – peak vertical ground reaction force. EMA - Effective mechanical advantage. 
 
 
 
 
 
 
 
 
 ExtMA @ peak AJM (cm) Peak AJM (Nm/kg) Peak GRF (N/kg) EMA 
Single limb stance time 
(s) 
Step length (m) 
Speed 
(m/s) 
Ctrl DM DPN Ctrl DM DPN Ctrl DM DPN Ctrl DM DPN Ctrl DM DPN Ctrl DM DPN 
0.6 
11.71  
(3.74) 
11.79  
(3.14) 
9.54  
(4.41)** 
1.53 
(0.53) 
1.47 
(0.47) 
1.28 
(0.45)** 
9.91 
(2.81) 
9.63 
(2.70) 
11.22 
(3.27)** 
0.402 
(0.09) 
0.424 
(0.06)** 
0.486 
(0.08)** 
0.90 
(0.20) 
0.84 
(0.23) 
0.96 
(0.05)** 
0.59 
(0.20) 
0.57  
(0.24) 
0.51  
(0.09)** 
0.8 
9.81  
(4.14) 
10.03  
(3.47) 
10.22  
(4.01) 
1.69 
(0.59) 
1.57 
(0.50) 
1.32 
(0.41)** 
10.84 
(2.87) 
10.52 
(2.78) 
11.91 
(3.38)** 
0.458 
(0.07) 
0.473 
(0.04)** 
0.462 
(0.07) 
0.80 
(0.15) 
0.84 
(0.21) 
0.96 
(0.05)** 
0.63 
(0.21) 
0.57  
(0.21) 
0.53  
(0.05)** 
1.0 
10.25  
(3.57) 
10.30  
(3.68) 
9.70  
(4.98)** 
1.52 
(0.53) 
1.45 
(0.57) 
1.40 
(0.52) 
10.80 
(2.74) 
11.13 
(2.70) 
12.74 
(3.02)** 
0.460 
(0.06) 
0.465 
(0.11) 
0.485 
(0.09)** 
0.71 
(0.13) 
0.74 
(0.05) 
0.88 
(0.05)* 
0.69 
(0.15) 
0.67  
(0.05) 
0.64  
(0.04)* 
1.2 
9.51  
(3.71) 
9.63  
(4.03) 
9.48 
(4.55) 
1.74 
(0.60) 
1.50 
(0.58)** 
1.56 
(0.55)** 
12.01 
(2.94) 
11.78 
(2.82) 
12.97 
(3.17) 
0.486 
(0.04) 
0.488 
(0.08) 
0.494 
(0.05)** 
0.58 
(0.31) 
0.62 
(0.05) 
0.68 
(0.06)* 
0.76 
(0.11) 
0.75  
(0.17) 
0.69 
(0.07)* 
1.4 
11.02  
(4.65) 
9.97  
(4.81)** 
8.46  
(5.54)** 
1.99 
(0.74) 
1.68 
(0.66)** 
1.46 
(0.55)** 
12.25 
(3.08) 
12.74 
(3.01) 
14.52 
(3.43)** 
0.426 
(0.05) 
0.461 
(0.04)** 
0.508 
(0.06)** 
0.56 
(0.15) 
0.58 
(0.21) 
0.62 
(0.14)* 
0.79 
(0.12) 
0.77  
(0.17) 
0.71 
(0.11)* 
1.6 
10.24  
(5.40) 
10.18  
(5.49) 
10.43  
(6.14) 
2.09 
(0.81) 
1.80 
(0.67)** 
1.62 
(0.60)** 
13.13 
(3.28) 
11.28 
(2.86)** 
14.16 
(3.48)** 
0.460 
(0.03) 
0.451 
(0.04) 
0.493 
(0.09)** 
0.50 
(0.15) 
0.50 
(0.11) 
0.53 
(0.01)* 
0.81 
(0.11) 
0.80  
(0.04) 
0.74 
(0.02)* 
Mean 
10.42  
(4.20) 
10.31 
(4.10) 
9.63  
(4.93)** 
1.74 
(0.64) 
1.59 
(0.56)** 
1.44 
(0.51)** 
9.82 
(2.95) 
11.18 
(2.81)** 
12.92 
(3.29)** 
0.448 
(0.05) 
0.460 
(0.06)** 
0.488 
(0.07)** 
0.68 
(0.18) 
0.68 
(0.14) 
0.77 
(0.06)** 
0.71 
(0.15) 
0.68 
(0.14) 
0.63 
(0.06)** 
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Table 3. Ankle, knee and hip joint ranges of motion (RoM) over the gait cycle at different matched speeds. 
 
 
 
 
 
 
 
 
 
 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and diabetic patients with moderate/severe neuropathy 
(DPN, n=14). Significant differences from the Ctrl group are denoted by *(P<0.05) or **(P<0.01). Values are means (standard deviations). 
RoM – range of motion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RoM Ankle (deg) RoM Knee (deg) RoM Hip (deg) 
Speed (m/s) Ctrl DM DPN Ctrl DM DPN Ctrl DM DPN 
0.6 23.1 (8.1) 22.7 (7.8) 20.8 (9.5)** 64.5 (24.4) 62.6 (23.7) 61.2 (27.4)** 44.9 (16.5) 42.4 (12.7) 40.8 (15.8)** 
0.8 23.7 (7.4) 23.5 (8.5) 21.1 (7.8)** 66.6 (27.6) 64.8 (28.3)** 62.7 (29.1)** 46.6 (17.9) 43.1 (15.8)** 42.9 (16.0)** 
1.0 25.6 (9.0) 24.4 (8.3)* 22.5 (9.4)** 67.7 (25.1) 66.1 (21.2)** 64.9 (24.0)** 46.8 (14.8) 44.8 (16.6)** 42.1 (19.3)** 
1.2 26.4 (7.5) 25.2 (8.7)* 23.7 (8.4)** 69.4 (22.9) 67.7 (26.6)** 66.5 (27.3)** 47.9 (16.7) 44.5 (15.7)** 43.2 (18.7)** 
1.4 26.8 (10.3) 26.0 (9.1) 23.4 (9.2)** 69.8 (27.8) 69.3 (25.8) 67.3 (30.4)** 49.8 (13.7) 47.3 (14.2)** 45.7 (15.3)** 
1.6 27.3 (9.9) 26.9 (8.6) 24.3 (9.0)** 71.0 (28.4) 70.3 (31.2) 68.4 (30.7)** 50.7 (19.4) 48.4 (18.9)** 46.5 (21.4)** 
Mean 25.4 (8.7) 24.7 (8.5) 22.4 (8.8)** 68.2 (26.0) 66.8 (26.1)** 65.2 (28.1)** 47.8 (16.5) 45.1 (16.7)** 43.5 (17.8**) 
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Table 4. Peak joint angle values for the ankle, knee and hip during the gait cycle at different matched speeds. 
 
 Peak ankle angle Peak knee angle Peak hip angle 
Speed 
(m/s) 
Ctrl DM DPN Ctrl DM DPN Ctrl DM DPN 
DF PF DF PF DF PF Flex Ext Flex Ext Flex Ext Flex Ext Flex Ext Flex Ext 
0.6 10.3 12.8 10.1 12.6 8.3** 12.5 55.2 9.3 53.0 9.6 51.0** 10.2** 37.7 7.2 36.8 5.6** 38.0 2.8** 
0.8 10.4 13.3 10.4 13.1 8.1** 13.0 57.4 9.2 55.3 9.5 52.6** 10.1** 38.7 7.9 37.3 5.8** 38.1 4.8** 
1.0 10.4 15.2 9.8 14.6 7.9** 14.6 59.5 8.2 57.4 8.7 56.0 8.9 38.0 8.8 37.5 7.3 38.6 3.5** 
1.2 10.5 15.9 10.1 15.1 8.6** 15.1 61.0 8.4 58.9 8.8 57.3** 9.2** 38.1 9.8 38.4 6.1** 39.8** 3.4** 
1.4 10.7 16.1 10.6 15.4 8.2** 15.2** 64.3 5.5 62.9 6.4** 59.9** 7.4** 36.2 13.6 39.1** 8.2** 40.1** 5.6** 
1.6 10.9 16.4 11.5 15.4 9.0** 15.3** 67.6 3.4 66.1 4.2** 61.9** 6.5** 35.5 15.2 39.3** 9.1** 42.4** 4.1** 
Mean 10.5 14.9 10.3 14.4 8.1** 14.3 60.8 7.4 59.0 7.8 56.5** 8.7** 37.4 10.4 38.0 7.1** 39.5** 4.0** 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and diabetic patients with moderate/severe neuropathy 
(DPN, n=14). Significant differences from the Ctrl group are denoted by *(P<0.05). Values are means. DF – dorsflexion, PF – plantarflexion, 
Flex – flexion, Ext – extension. 
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Figure 4. Effective mechanical advantage (EMA) values across the entire stance 
phase. Line graphs: Ctrl - solid line, DM - dotted line, DPN - dashed line. Values 
are means. 
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3.5 DISCUSSION 
I have recently shown that patients with diabetes and especially those with DPN 
have a higher CoW compared to controls (32). In the present study I investigated 
whether differences between diabetes patients and healthy controls in the ExtMA 
and EMA around the ankle joint could be potential mechanisms underpinning the 
above finding. I established that patients with diabetes and especially those with 
DPN have a smaller ExtMA and a higher mechanical advantage around the ankle 
joint compared to controls (Fig. 3; Table 2), which is in contrast with our 
hypothesis that the ExtMA will be higher and the EMA will lower in the diabetes 
patients. 
The smaller ExtMA at the ankle in patients with diabetes and especially those 
with DPN was evident across all walking speeds (Table 2) and means that either 
the resultant GRF was applied closer to the ankle joint centre, or the angle of 
application was more towards the ankle, making the ExtMA smaller, thereby 
minimising the ankle joint moment. The effects of this can be seen by the reduced 
ankle joint moment in patients with DPN compared to controls across all matched 
walking speeds (Table 2). 
It is has previously been shown that diabetes patients reduce joint moments by 
taking shorter strides with less flexed joints (2, 23, 29, 31, 33, 9). Our unexpected 
findings demonstrate a mechanism through which people with diabetes and 
particularly those with DPN reduce the joint moment at the ankle during walking 
– by applying the GRF more proximally on the foot or at an angle more towards 
the ankle, reducing the ExtMA around the ankle and thereby reducing the ankle 
joint moment (Figs. 2 & 3). No differences in foot length existed to explain the 
smaller ExtMA found in patients with DPN (Table 1) and further, this parameter 
(foot length) was also entered as a covariate in the statistical analysis of variance. 
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Our finding of a smaller ExtMA and greater EMA around the ankle does not 
appear to explain an increased CoW, as the plantarflexor muscles would need to 
produce not higher, but smaller contractile forces to rotate the foot and propel the 
body forward. However, the consequent reduction in the force applied to the 
Achilles tendon would result in reduced tendon elongation and therefore reduced 
storage of elastic strain energy. The reduced contribution from elastic strain 
energy stored in the Achilles tendon could impact upon the CoW, but this requires 
further investigation.  
The joint kinematics from the present study provides insight as to how patients 
with DPN might have been able to execute this natural strategy of reducing the 
ExtMA around the ankle and thereby minimising the ankle joint moment. The 
ankle joint RoM over the gait cycle was reduced in patients with DPN compared 
to controls as a result of a reduced peak dorsiflexion angle (Tables 3 & 4). This 
reduced dorsiflexion suggests that patients with DPN were not able to allow the 
tibia to rotate over the foot to the same extent as controls during the mid-stance 
phase, further evidenced by the reduced knee flexion (Table 4), thereby applying 
force to the ground more proximally on the foot and reducing the ExtMA around 
the ankle as a result. These joint range of motion limitations may also raise the 
possibility that this may not be a natural strategy of choice, but rather in contrast, 
patients with DPN may adopt this strategy since they have no other possibilities 
due to such limitations. 
Whilst the total hip joint RoM during walking was reduced in diabetes patients 
and especially those with DPN compared to controls (Table 3), patients with 
diabetes and to the greatest extent those with DPN flexed the hip more than 
controls (Table 4). This kinematic strategy fits very well with the ‘hip strategy’ 
previously reported in other studies (31, 34), whereby diabetes patients have 
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been observed to ‘drag’ the leg forwards into the swing phase from the hip, rather 
than ‘propelling’ the leg off from the ground using the ankle plantarflexors. Whilst 
greater knee and hip RoM occurs with increasing walking speeds in all groups, a 
consistently smaller RoM at the knee and hip in the DPN group (Table 3) 
underlies the shorter step length reported in the present study and is comparable 
with a number of previous studies conducted in diabetes patients (47, 34, 28, 15, 
1, 31, 32).  
Through measuring the ExtMA during walking and the internal Achilles tendon 
moment arm in the weight-bearing condition using MRI, I calculated the EMA 
around the ankle. The present study found a greater value for the EMA at the 
ankle joint in diabetes patients and especially in those with DPN compared to 
controls (Table 2). To the best of our knowledge there are no previous studies 
reporting the EMA in diabetes patients during walking, but it has been measured 
for different human and animal populations (4, 40, 42, 17, 3). The internal AT 
moment arm values in the present study (Table 1) measured using MRI are 
comparable with those reported from previous human studies conducted in other 
populations reporting values ranging between 3.7 and 5.3 cm (26, 4, 38, 43). The 
EMA was calculated throughout the stance phase (Fig. 4), but the most 
functionally relevant point to report was considered to be from 50% till 100% of 
the stance phase. Figure 4 shows that for the same joint work there is still a higher 
CoW in DPN. 
Whilst previous studies have consistently reported lower ankle joint moments in 
diabetes patients during walking, this has typically been at the self-selected 
speed, which is consistently lower in diabetes patients as they seek to minimise 
the demands of the task. Here I show that when walking speed is matched, joint 
moments are consistently lower in the DM and particularly in the DPN group 
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compared to controls (Table 2). The reduction in the ExtMA and increasing the 
EMA at the ankle in the diabetes groups is relatively independent of walking 
speed, whereas ankle joint moments and the vertical GRF increase with 
increasing walking speed (Table 2). It is also noteworthy that although the peak 
ankle joint moments were significantly lower in the diabetes groups compared to 
controls, the vertical GRF was significantly higher especially in the DPN group 
(Table 2). This higher GRF seems to underline the importance of the strategy in 
patients with diabetes and particularly those with DPN for reducing the ExtMA 
around the ankle to lower the ankle joint moment substantially below that of 
controls. What remains unclear is whether the way in which the DPN group 
walked represents a natural strategy to lower the demands, or whether they have 
no other possibility to walk differently because of any foot deformities present and 
inflexible joints in the lower limb and within the foot. 
In terms of study limitations, the mean body mass was significantly different 
between groups (being higher in the DPN group), however, this should not affect 
the ankle ExtMA, EMA, or the joint moments since these were normalised for 
body mass. Furthermore, the higher body mass of patients with DPN is a well-
known characteristic of this clinical population described by previous studies (23, 
20, 21). Although only a mean of 10 years difference, patients in the DPN group 
were significantly older than controls (66 to 56 years, respectively), which might 
be a confounding factor for some of the variables examined, but unlikely to affect 
the main variables of interest: the ankle ExtMA and EMA. 
 
 
 
97 
 
3.6 REFERENCES 
1. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint mobility (LJM) in 
elderly subjects with type II diabetes mellitus. Arch Gerontol Geriat 53: 135–40, 
2011. 
 
2. Allet L, Armand S, de Bie R, Pataky Z, Aminian K, Herrmann FR, de 
Bruin ED. Gait alterations of diabetic patients while walking on different surfaces. 
Gait Posture 29: 488–493, 2009. 
 
3. Arampatzis A, Monte G De, Karamanidis K, Morey-Klapsing G, 
Savvas S, Brüggemann GP. Influence of the muscle-tendon unit’s mechanical 
and morphological properties on running economy. J Exp Biol 209: 3345–3357, 
2006. 
 
4. Biewener A. Biomechanical consequences of scaling. J Exp Biol 208: 
1665–1676, 2005. 
 
5. Biewener A, Farley CT, Roberts TJ, Temaner M. Muscle mechanical 
advantage of human walking and running: implications for energy cost. J Appl 
Physiol 97: 2266–2274, 2004. 
 
6. Boulton AJM. Management of Diabetic Peripheral Neuropathy. Clin Diab 
23: 9–15, 2005. 
 
7. Bringer J, Fontaine P, Detournay B, Nachit-Ouinekh F, Brami G, 
Eschwege E. Prevalence of diagnosed type 2 diabetes mellitus in the French 
general population: The INSTANT study. Diabetes and Metabolism 35: 25–31, 
2009. 
 
8. Brown SJ, Handsaker JC, Bowling FL, Boulton AJM, Reeves ND. 
Diabetic peripheral neuropathy compromises balance during daily activities. 
Diabetes Care 6: 1116-1122, 2015. 
 
9. Brown SJ, Handsaker JC, Bowling FL, Maganaris CN, Boulton AJM, 
Reeves ND. Do patients with diabetic neuropathy use a higher proportion of their 
maximum strength when walking? J Biomech 47: 3639–3644, 2014. 
 
10. Chiles NS, Phillips CL, Volpato S, Bandinelli S, Ferrucci L, Guralnik 
JM, Patel KV. Diabetes, Peripheral Neuropathy and Lower Extremity Function. J 
Diabetes Complicat 28: 91–95, 2014. 
 
11. Courtemanche R, Teasdale N, Boucher P, Fleury M, Lajoie, Y, Bard C. 
Gait problems in diabetic neuropathic patients. Arch Phys Med Rehabil 77: 849–
855, 1996. 
 
12. Cronin NJ, Peltonen J, Ishikawa M, Komi PV, Avela J, Sinkjaer T, 
Voigt M. Achilles tendon length changes during walking in long-term diabetic 
patients. Clin Biomech 25: 476–482, 2010. 
 
13. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of 
diabetes and diabetes-related complications. Phys Ther 88: 1254–1264, 2008. 
98 
 
14. Fernando M, Crowther R, Lazzarini P, Sangla K, Cunningham M, 
Buttner P, Golledge J. Biomechanical characteristics of peripheral diabetic 
neuropathy: A systematic review and meta-analysis of findings from the gait 
cycle, muscle activity and dynamic barefoot plantar pressure. Clin Biomech 28: 
831–845, 2013. 
 
15. Gomes AA, Onodera AN, Otuzi ME, Pripas D, Mezzarane, RA, Sacco 
IC. Electromyography and kinematic changes of gait cycle at different cadences 
in diabetic neuropathic individuals. Muscle Nerve 2: 258–268, 2011. 
 
16. Grant WP, Foreman EJ, Wilson AS, Jacobus DA, Kukla RM. Evaluation 
of Young’s modulus in Achilles tendons with diabetic neuroarthropathy. J Am 
Podiat Med Assn 95: 242-246, 2005. 
 
17. Gregersen CS, Carrier DR. Gear ratios at the limb joints of jumping dogs. 
J Biomechanics 37: 1011–1018, 2004. 
 
18. Handsaker JC, Brown SJ, Bowling FL, Cooper G, Maganaris CN, 
Boulton AJM, Reeves N. Contributory factors to unsteadiness during walking up 
and down stairs in patients with diabetic peripheral neuropathy. Diabetes Care 
37: 3047-3053, 2014. 
 
19. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. 
Brussels, Belgium: International Diabetes Federation, 2013. 
http://www.idf.org/diabetesatlas 
 
20. Ijzerman TH, Schaper NC, Melai T, Meijer K, Willems PJB, Savelberg 
HHCM. Lower extremity muscle strength is reduced in people with type 2 
diabetes, with and without polyneuropathy, and is associated with impaired 
mobility and reduced quality of life. Diabetes Res Clin Pr 95: 345–351, 2011. 
 
21. Jor’dan AJ, Manor B, Novak V. Slow gait speed - an indicator of lower 
cerebral vasoreactivity in type 2 diabetes mellitus. FNAGI 6: 1-9, 2014. 
 
22. Katoulis EC, Ebdon-Parry M, Hollis S, Harrison AJ, Vilejkite L, 
Kulkarni J, Boulton AJM. Postural instability in neuropathics diabetics patients 
at risk of foot ulceration. Diabetes Med 14: 296–300, 1997. 
 
23. Ko SU, Stenholm S, Chia CW, Simonsick EM, Ferrucci L. Gait pattern 
alterations in older adults associated with type 2 diabetes in the absence of 
peripheral neuropathy-Results from the Baltimore Longitudinal Study of Aging. 
Gait Posture 34: 548–552, 2011. 
 
24. Kwon O, Minor SD, Maluf KS, Mueller MJ. Comparison of muscle activity 
during walking in subjects with and without diabetic neuropathy. Gait Posture 18: 
105–113, 2003. 
 
25. Maganaris CN. Imaging-based estimates of moment arm length in intact 
human muscle-tendons. Eur J Appl Physiol 91: 130–139, 2004. 
 
26. Maganaris CN, Baltzopoulos V, Sargeant AJ. Changes in Achilles 
tendon moment arm from rest to maximum isometric plantarflexion: J Physiology 
99 
 
510: 977–985, 1998. 
 
27. Maluf KS, Mueller MJ. Comparison of physical activity and cumulative 
plantar tissue stress among subjects with and without diabetes mellitus and a 
history of recurrent plantar ulcers. Clin Biomech 7: 567-575, 2003. 
 
28. Martinelli AR, Mantovani AM, Nozabieli AJL, Ferreira DMA, Barela JA, 
Camargo MR De, Fregonesi CEPT. Muscle strength and ankle mobility for the 
gait parameters in diabetic neuropathies. Foot 23: 17–21, 2013. 
 
29. Menz HB, Lord SR, St George R, Fitzpatrick RC. Walking stability and 
sensorimotor function in older people with diabetic peripheral neuropathy.  Arch 
Phys Med Rehabil 85: 245–252, 2004. 
 
30. Morrato EH, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical 
activity in U.S. adults with diabetes and at risk for developing diabetes. Diabetes 
Care 2: 203-209, 2003. 
 
31. Mueller MJ, Sinacore DR, Hoogstrate, Daly L. Hip and ankle walking 
strategies, effect on peak plantar pressures and implications for neuropathic 
ulceration. Arch Phys Med Rehab 75: 1196–1200, 1994. 
 
32. Petrovic M, Deschamps K, Verschueren SM, Bowling FL, Maganaris 
CN, Boulton AJM, Reeves ND. Is the metabolic cost of walking higher in people 
with diabetes? J Appl Physiol 120: 55-62, 2016.  
 
33. Petrofsky J, Lee S, Bweir S. Gait characteristics in people with type 2 
diabetes mellitus. Eur J Appl Physiol 93: 640–647, 2005. 
 
34. Rao S, Saltzman C, Yack HJ. Ankle ROM and stiffness measured at rest 
and during gait in individuals with and without diabetic sensory neuropathy. Gait 
Posture 3: 295–301, 2006. 
 
35. Reeves ND, Najafi B, Crews RT, Bowling FL. Aging and type 2 diabetes: 
Consequences for motor control, musculoskeletal function, and whole-body 
movement. J Aging Res. Article ID 508756, 2013. 
 
36. Ren L, Miller CE, Lair R, Hutchinson JR. Integration of biomechanical 
compliance, leverage, and power in elephant limbs. Proceedings of the National 
Academy of Sciences of the United States of America, 107: 7078–7082, 2010. 
 
37. Reuleaux F. Theoretische Kinematik: Grundzuge einer Theorie des 
Maschinenwesens. F. Vieweg, Braunschweig, MacMillan, London. Kennedy 
ABW (trans) (1963). The kinematics of machinery: outline of a theory of 
machines. New York, 56–70, 1875. 
 
38. Rugg SG, Gregor RJ, Mandelbaum BR, Chiu L. In vivo moment arm 
calculations at the ankle using magnetic resonance imaging (MRI). J 
Biomechanics 23: 495–501, 1990. 
 
39. Sammarco GJ, Burstein AH, Frankel VH. Biomechanics of the ankle: a 
kinematic study. Orthop Clin North Am 4: 75–96, 1973. 
100 
 
 
40. Scholz MN, Bobbert MF, van Soest J, Clark JR, van Heerden J. 
Running biomechanics: shorter heels, better economy. J Exp Biol 211: 3266–
3271, 2008. 
 
41. Siegler S, Chen J, Schneck CD. The three-dimensional kinematics and 
flexibility characteristics of the human ankle and subtalar joints. Part 1: 
Kinematics. J Biomech Eng 110: 364–373, 1998. 
 
42. Smith NC, Wilson M. Mechanical and energetic scaling relationships of 
running gait through ontogeny in the ostrich (Struthio camelus). J Exp Biol 216: 
841–849, 2013. 
 
43. Spoor CW, Van Leeuwen JL, Meskers CGM, Titulaer AF, Huson A. 
Estimation of instantaneous moment arms of lower-leg muscles. J Biomechanics 
23: 1247-1259, 1990. 
 
44. Tamayo T, Rosenbauer J, Wild SH, Spijkerman MW, Baan C, Forouhi 
NG, Herder C, Rathmann W. Diabetes in Europe: An update. Diabetes Res Clin 
Pract 103: 206–217, 2014. 
 
45. Tudor-Locke C, Bassett DR Jr. How many steps/day are enough? 
Preliminary pedometer indices for public health. Sports Med 1: 1-8, 2004. 
 
46. Tudor-Locke CE, Bell RC, Myers AM, Harris SB, Lauzon N, Rodger 
NW. Pedometer-determined ambulatory activity in individuals with type 2 
diabetes. Diabetes Res Clin Pract 3: 191-199, 2002. 
 
47. Williams DSB, Brunt D, Tanenberg RJ. Diabetic neuropathy is related to 
joint stiffness during late stance phase. J Appl Biomech 23: 251–260, 2007. 
 
48. Yisahak SF, Beagley J, Hambleton IR, Narayan KMV. Diabetes in North 
America and The Caribbean: An update. Diabetes Res Clin Pr 103: 223–230, 
2014. 
 
 
 
 
 
 
 
101 
 
4. Experimental chapter three – Achilles tendon properties 
during walking in patients with diabetes: implications for 
metabolic energy saving 
 
4.1 ABSTRACT 
The Achilles tendon (AT) has the capacity to store and release elastic energy 
during walking, contributing to metabolic energy savings. In diabetes patients, it 
is hypothesised that a stiffer tendon may reduce the capacity of the tendon for 
energy saving, thereby contributing to an increased metabolic cost of walking in 
this population. The aim of this study was to investigate the effects of diabetes 
and diabetic peripheral neuropathy (DPN) on plantarflexion muscle-tendon 
behaviour during walking at self-selected and a controlled (1.0 m/s) walking 
speed. 23 non-diabetic controls (Ctrl); 20 diabetic patients without peripheral 
neuropathy (DM) and 13 patients with moderate/severe DPN, underwent gait 
analysis using a motion analysis system, force plates and ultrasound 
measurements from the gastrocnemius muscle. The DM and particularly the DPN 
group displayed significantly lower Achilles tendon elongation, higher stiffness 
(Ctrl: 210; DM: 231; DPN: 240 N/mm) and higher hysteresis (Ctrl: 18; DM: 21; 
DPN: 24 %) while walking compared to controls. The muscle fascicles of the 
gastrocnemius underwent very small length changes. Achilles tendon forces 
were lower in the diabetes groups compared to controls (Ctrl: 2666; DM: 2609; 
DPN: 2150 N). The results strongly point towards the reduced energy saving 
capacity of the Achilles tendon in diabetes patients as an important factor 
contributing to the increased metabolic CoW in these patients. 
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4.2 INTRODUCTION 
Diabetes mellitus (DM) is a common problem in older adults worldwide and is 
associated with many complications such as cardiovascular diseases, 
nephropathy, stroke, peripheral arterial disease, retinopathy, skin problems, poor 
wound healing and peripheral neuropathy (16, 14). One of the most common 
complications in diabetes is diabetic peripheral neuropathy (DPN). The incidence 
of DPN has been reported to range between 13 and 68% in diabetes populations 
(41); while Boulton (6) reports up to 50% of diabetes patients are affected by 
neuropathy.  
Scientists and clinicians are particularly interested in the impact of diabetes and 
DPN on gait and mobility since it has a direct impact on person’s quality of life. 
Diabetes has been reported to affect level walking, stair negotiation and cause 
impairments to balance control during walking and standing (13, 29, 42, 19, 5). 
The muscle-tendon complex is central to all movement tasks, with skeletal 
muscle generating force, which is transmitted to the skeleton via viscoelastic 
tendons. In addition to their force transmitting role, tendons can also play an 
important role in energy saving by storing (during stretching) and returning (during 
recoil) elastic energy (36, 37, 38, 2). In particular, the Achilles tendon is important 
for storing and releasing elastic energy during walking and can lead to significant 
metabolic energy savings, as it actually ‘spares’ the muscle from performing a 
large part of the work (3).  
Both muscles and tendons are highly malleable tissues, which can modify their 
properties in response to the level of physiological loading and also the metabolic 
environment (35, 1, 17). Animal studies show that diabetes causes non-
enzymatic glycation of soft tissues, such as tendon (33). This non-enzymatic 
glycation causes increased cross-linking, increasing the stiffness and modulus of 
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the tendon (32, 34). Stiffening of the tendon reduces the degree to which it can 
be stretched, affecting its potential for storing (and subsequently releasing) 
elastic strain energy during walking and also limiting the range of joint motion (11, 
18, 27). In humans, calcification and fascicle disruption have been observed in 
the diabetic human Achilles tendon (AT) (4). Since tendons exhibit relatively low 
mechanical hysteresis, most of the elastic energy stored during stretching is 
returned on recoil (25), but there is the capacity for hysteresis to also be affected 
by diabetes as has been shown to occur in human ageing (36).  
Cronin et al. (10) found the Achilles tendon length changes during walking at self-
selected speed to be attenuated in diabetes patients and that they were inversely 
correlated with diabetes duration. In dynamometry tests, Couppé et al. (10) found 
Achilles tendon stiffness and skin connective tissue cross-linking were greater in 
diabetes patients compared with controls.  
The role of the Achilles tendon during walking and the relative contribution 
required from the plantarflexors muscles remains unknown in diabetes patients. 
The aim of this study was to investigate the effects of diabetes and diabetic 
peripheral neuropathy on muscle and tendon behaviour during walking at self-
selected and a controlled speed. I hypothesized that the AT would contribute less 
to elastic energy during walking due to its increased stiffness in diabetes patients 
compared to controls and as a result a greater contribution would be required 
from the plantarflexor muscles, requiring more energy and contributing to explain 
the higher cost of walking (CoW) in people with diabetes. 
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4.3 MATERIALS AND METHODS 
Participants 
After receiving ethical approval for the study from all relevant bodies, a total of 
sixty seven participants were recruited, who gave their written informed consent 
to participate. Due to logistical reasons the measurements for this study were 
acquired in 56 of these participants. All participants were aged over 40 and 
allocated into one of three groups based upon defined criteria: patients with 
diabetes and moderate-severe peripheral neuropathy (DPN, n=13), patients with 
diabetes but no neuropathy (DM, n=20) and healthy controls without diabetes or 
peripheral neuropathy (Ctrl, n=23). Major exclusion criteria included: disorders of 
the vestibular system severe vascular disease, neurological, rheumatic disease, 
cerebral injury, unstable ischemic heart, musculoskeletal injury, foot or lower limb 
amputation (amputation of the hallux; amputation of more than two lesser toes on 
one foot; amputation of part of/whole foot) and open foot ulcer and recent surgery 
affecting gait. Information about the duration and type of diabetes, smoking habits 
and use of current medication were obtained by using a questionnaire. The vast 
majority of the DM and the DPN patients reported taking insulin, cholesterol-
lowering medication and diabetes medication. Participant characteristics are 
displayed in Table 1. 
 
Diagnosis of Diabetic Peripheral Neuropathy  
The presence and severity of peripheral neuropathy was assessed through 
clinical evaluation, which was undertaken to quantify neuropathy in diabetes 
patients and to confirm the absence of neuropathy in controls. Peripheral 
neuropathy was assessed by using the modified Neuropathy Disability Score 
(mNDS) and the vibration perception threshold (VPT). The mNDS is a composite 
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score taken from tests measuring the participant’s ability to discriminate 
temperature, detect pain, vibration and the Achilles tendon reflex (6). The VPT is 
an assessment performed using the probe of a neurothesiometer on the apex of 
the hallux and increasing the level of vibration until detected by the participant. A 
random blood glucose test was performed in the Ctrl group to confirm the 
absence of diabetes (<7 mmol/l) and the above neuropathy tests conducted to 
confirm the absence of neuropathy in the Ctrl group resulting from any aetiology. 
 
Gait analysis 
Gait analysis was performed for the purpose of assessing the contribution of the 
plantarflexor muscle-tendon complex and the capacity for elastic energy storage 
and release via the Achilles tendon. Participants were asked to walk along a 10-
metre walkway in the gait laboratory at their self-selected speed, as well as at 
standardized speed of 1.0 m/s. Walking at the standardized speed was controlled 
by measuring the velocity of a marker attached to the sacrum after each trial from 
the motion analysis data and providing immediate feedback for participants as to 
whether they needed to walk more quickly or more slowly on the next trial to 
achieve the required speed (1.0 m/s). Kinematic data were collected at 100 Hz 
using a 10-camera Vicon motion capture system (Vicon, Oxford, UK) a full-body 
modified Plug-In-Gait marker set consisting of 54 markers. Where possible 
motion analysis markers were placed directly onto the skin; to minimise 
movement artefacts resulting from loose clothing all participants wore tight-fitting 
shorts and t-shirts. Ground reaction forces were measured at 1000 Hz from three 
force platforms (Kistler, Zurich, Switzerland) embedded into the walkway and 
synchronised with the kinematic data. Walking trials were repeated until at least 
three ‘clean’ foot contacts with the force platforms were made with each limb, for 
106 
 
both speed conditions. During walking, an ultrasonographic imaging device 
(Aloka SSD-5000, Tokyo, Japan) operating at 25 Hz was used to measure 
gastrocnemius medialis (GM) muscle fascicle length changes in vivo. For these 
measurements, a linear 7.5 MHz probe with 60 mm field of view was tightly 
secured around the right lower leg in the mid-sagittal plane of the GM muscle with 
a custom-built fixation device (Fig. 1). The ultrasound scanning was synchronized 
with recordings of the kinematic and kinetic data. All participants wore specialist 
diabetic shoes (MedSurg, Darco, Raisting, Germany) with a neutral foot-bed, 
ensuring the diabetic patients walked with safe, appropriate footwear whilst 
minimising the effect of footwear by standardising across all participants (Fig. 1). 
 
Figure 1. A linear 7.5 MHz probe (A) with 60 mm field of view. A custom-built 
fixation device made of Velcro straps and a plastic cast molded to fit the general 
contour of the calf (B) was used to secure the probe around the left lower leg, in 
the mid-sagittal plane of the gastrocnemius muscle (C) (Fukunaga et al., 2001). 
 
Dynamometry measurements: Measurement of Maximal Plantarflexion 
Strength 
Isometric plantarflexor maximal voluntary contraction (MVC) joint moment 
(maximum strength) was recorded with participants laying prone with the knee in 
full extension. The axis of rotation of the ankle, defined as the line connecting the 
two malleoli, was carefully aligned with the axis of rotation of the dynamometer 
and the right foot secured to the foot adapter of an isokinetic dynamometer 
(Cybex NORM, Cybex International, New York, NY, USA). Straps were used 
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around the ankle and also the hips to prevent extraneous movements during 
maximal plantarflexions. Prior to testing subjects became familiarised with the 
procedures involved. Participants were instructed to perform maximal isometric 
plantarflexion contractions at joint angles of 0, 5 and 10 degrees of dorsiflexion, 
where zero degrees was neutral ankle position: the footplate of the dynamometer 
perpendicular to the longitudinal axis of the tibia. The subjects were verbally 
encouraged for additional motivation to perform static contractions with the ankle 
plantarflexor with a maximum possible effort at all three ankle angles and they 
were encouraged to hold each contraction for up to 5-6 s. Contractions were 
performed in a randomized order. Two contractions were performed at each ankle 
angle by allowing a 1-min rest interval between bouts and the highest value was 
considered as the MVC at that ankle angle. Results were subsequently 
normalised to body mass. 
 
Data processing 
The purpose of the data analysis was to quantify the plantarflexor muscles and 
Achilles tendon characteristics during walking. The gastrocnemius medialis (GM) 
muscle was assessed as a representative of the plantarflexor muscle group (39, 
40). The GM muscle fascicle lengths were measured from every frame of the 
ultrasound recordings during the entire stance phase. On each ultrasound frame, 
three lines were defined automatically using a custom-script written in MATLAB 
software (12): one line tracked the superficial aponeurosis, a second line was 
matched with the deep aponeurosis, and a third line defined the fascicular path 
of the fascicle movement. From these three lines, fascicle length and pennation 
angle were calculated on each frame of ultrasound data. The pennation angle 
was defined as the angle that the fascicle made with the deep aponeurosis. 
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Muscle fascicle length was defined as the distance between the superficial and 
deep aponeurosis parallel to the lines of collagenous tissue (Fig. 2). Pennation 
angle (α) was defined as the angle between the collagenous tissue and the deep 
aponeurosis. The equations by Menegaldo et al. (28) were used to calculate the 
GM muscle-tendon complex (MTC) length change (muscle plus free tendon and 
aponeurosis in both distal and proximal ends) using the fascicle length changes 
and the ankle and knee joint displacements measured during walking over the 
stance phase. The length of the tendon (including both the free tendon and 
aponeurosis) was found by subtracting muscle fascicle length projected in the 
direction of the line of force application from the muscle–tendon complex (MTC) 
length for each time instant. Thus: 
l t = l MTC – l m cos α 
 
where l t is the length of the tendon, l MTC is the length of the MTC, l m is the 
ultrasound-measured muscle fascicle length, and α is the ultrasound-measured 
pennation angle. Muscle fascicle and tendon properties were assumed to be 
consistent along the length of the MTC. The muscle fascicles were also assumed 
to be parallel to one another. The validity and reliability of the ultrasound 
measurements in vivo during walking have been critically assessed in other 
studies on the same and similar populations, reporting ICC values between 0.78 
and 0.94 (11, 26, 30, 39). 
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Figure 2. Typical sonograph of the GM muscle. The fascicular trajectory between 
the two aponeurosis, as well as the pennation angle (α) are highlighted in white. 
SA, superficial aponeurosis; GM, gastrocnemius medialis muscle; DA, deep 
aponeurosis. 
 
Achilles tendon force 
Achilles tendon (AT) forces were calculated during walking throughout the stance 
phase by dividing the net plantarflexion joint moments (Nm) by the AT internal 
moment arm length (m). The plantarflexion joint moments were derived from the 
kinematic and kinetic data using Visual 3D software (C-motion Inc., MD, USA). 
MRI scanning and analysis was used to quantify the internal AT moment arm 
length at the ankle as previously described (24). Elongation of the AT was 
calculated as described in the above section. The AT force and elongation were 
normalised to 100 points to represent the entire stance phase. Therefore, the AT 
force-elongation curve was derived, as shown in Figs. 5 and 6, where the loading 
phase (arrow pointing up) represents 10-70% of the stance phase and the 
unloading phase (arrow pointing down) the remaining 30%, as described in Table 
2. The area between the loading and unloading curves represents the AT’s 
hysteresis, which is the energy dissipated upon recoil.  
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Stiffness and hysteresis during walking 
The AT stiffness was calculated from the measurements taken during walking as 
the slope of the loading curve by dividing the estimated tendon force (N) by the 
tendon’s elongation (mm) over a force region between 500 and 1500 N (26). The 
AT hysteresis was calculated by dividing the difference between the area under 
the loading and the unloading curves by the area under the loading curve alone. 
This provides a measure of the energy converted to heat, an important feature of 
the mechanical properties of tendon. The mechanical hysteresis was defined as 
the area between the loading (L) and unloading (UnL) curves and expressed as 
a percentage: 
Mechanical hysteresis = (L - UnL) / L∙100 
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to 
assess between group differences. If the ANOVA was significant, a Fisher’s least 
significant difference (LSD) post-hoc test was used to test for differences between 
the diabetes groups (DM and DPN) and the control group. All values presented 
are means and standard deviation. Significance was accepted at p<0.05. 
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4.4 RESULTS 
Participant characteristics  
Participant characteristics are shown in Table 1. There were no significant 
differences between the groups in age and BMI (Table 1). 
 
Neuropathy assessments  
As expected, the DPN group displayed significantly higher values for the VPT 
and the mNDS compared to the Ctrl group (Table 1). The VPT and mNDS for the 
DM group were not significantly different from the Ctrl, underlining that this 
diabetic patient group had no neuropathy (Table 1). 
 
Lower limb kinetics and kinematics during walking 
Peak ankle plantarflexion joint moments were significantly lower (P<0.01) in the 
DPN and the DM compared to the Ctrl group for both, self-selected and 1.0 m/s 
walking speeds (Table 2). A significantly (P<0.01) lower ankle and knee joint 
range of motion (RoM) was observed in the DPN and the DM groups compared 
to the Ctrl group for self-selected and 1.0 m/s walking speeds (Table 2). 
 
Plantarflexor muscle-tendon unit behaviour during walking  
There were no differences in the fascicle length during standing in the DPN and 
the DM groups compared to the Ctrl group (P>0.05). Average fascicle length 
change data show that the DPN group was significantly different (P<0.01) than 
the Ctrl group for both self-selected speed and 1.0 m/s, while the DM group was 
different than the Ctrl group only at 1.0 m/s. Significant differences (P<0.01) in 
the MTC length change were found between the DPN and the Ctrl as well as the 
DM and the Ctrl groups for both walking speeds (Table 2). There were significant 
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differences in the tendon length change between the groups at self-selected 
walking speed (Ctrl: 1.81 cm; DM 1.66 cm; DPN: 1.54 cm; P<0.01) as well as 1.0 
m/s (Ctrl: 1.67 cm; DM 1.51 cm; DPN: 1.47 cm; P<0.01), where the DPN group 
expressed smaller tendon length changes. The DM and particularly the DPN 
group displayed significantly lower Achilles tendon elongation, higher stiffness 
(Ctrl: 210; DM: 231; DPN: 240 N/mm: P<0.01) and higher hysteresis (Ctrl: 18; 
DM: 21; DPN: 24 %: P<0.01) while walking compared to controls. 
 
 
Table 1. Participant characteristics and results from neuropathy assessments. 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 55 (7) 57 (8) 61 (7) 
BMI (kg/m2) 26 (4) 28 (4) 29 (5) 
mNDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3) 8.2 (4) 27.4 (9)** 
Diabetes duration (years) - 14 (13) 17 (11) 
Type 1 diabetes - 6 4 
Type 2 diabetes - 14 9 
 
Healthy controls (Ctrl, n=23), diabetic patients with no neuropathy (DM, n=20) 
and diabetic patients with moderate/severe neuropathy (DPN, n=13). Significant 
differences from the Ctrl group are denoted by ** (P<0.01). BMI = body mass 
index, mNDS = modified neuropathy disability score, VPT = vibration perception 
threshold. Values are means (standard deviations). 
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Table 2. Plantarflexor muscle-tendon and Achilles tendon parameters during walking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gastrocnemius muscle fascicle length and other muscle-tendon parameters during walking for healthy controls (Ctrl; n=23), 
diabetic patients with no neuropathy (DM; n=20) and diabetic patients with moderate/severe neuropathy (DPN; n=13). Values 
are group means and SD; Significant differences from the Ctrl group are denoted by *(P<0.05) or **(P<0.01). MTC – muscle-
tendon complex; RoM – range of motion. 
 Ctrl DM DPN 
 Self-selected  Self-selected  Self-selected  
Walking speed (m/s) 1.43 1.0 1.33 1.0 1.30 1.0 
Stiffness (N/mm) 210 (41) 186 (34) 231 (46)** 194 (39)** 240 (49)** 202 (37)** 
Hysteresis (%) 18 (3) 17 (3) 21 (5)** 19 (4)* 24 (6)** 21 (5)** 
Standing fascicle length (cm) 5.15 (1.5) 5.08 (1.4) 5.19 (1.3) 
Fascicle length change (cm) 0.57 (0.06) 0.52 (0.16) 0.41 (0.04) 0.37 (0.04)** 0.35 (0.09)** 0.41 (0.12)** 
MTC length change (cm) 1.62 (0.3) 1.41 (0.4) 1.13 (0.4)** 0.95 (0.3)** 0.84 (0.3)** 0.63 (0.2)** 
Tendon length change (cm) 1.81 (1.0) 1.67 (0.7) 1.66 (0.5)* 1.51 (0.6)* 1.54 (0.8)** 1.47 (0.6)** 
Fascicle  length change (cm) 
10-70 % of stance (loading) 
0.58 (0.08) 0.53 (0.19) 0.42 (0.05)** 0.39 (0.06)** 0.38 (0.12)** 0.44 (0.14)** 
Fascicle  length change (cm) 
70-100% of stance (unloading) 
0.54 (0.04) 0.50 (0.12) 0.38 (0.04)** 0.33 (0.04)** 0.31 (0.07)** 0.37 (0.11)** 
MTC length change (cm) 
10-70 % of stance (loading) 
1.21 (0.2) 1.11 (0.3) 0.89 (0.3)** 0.81 (0.2)* 0.76 (0.2)** 0.69 (0.1)** 
MTC length change (cm) 
70-100% of stance (unloading) 
1.44 (0.1) 1.20 (0.1) 0.97 (0.1)** 0.84 (0.1)** 0.63 (0.1)** 0.58 (0.1)** 
Tendon length change (cm) 
10-70 % of stance 
1.96 (0.6) 1.71 (0.4) 1.65 (0.3)** 1.26 (0.4)** 1.18 (0.5)** 0.81 (0.4)** 
Tendon length change (cm) 
70-100% of stance 
1.92 (0.4) 1.82 (0.3) 1.63 (0.2)** 1.41 (0.2)** 0.78 (0.3)** 1.15 (0.2)** 
Achilles Tendon forces (N) 2666 (242) 2343 (288) 2609 (167)* 2256 (290)** 2150 (177)** 2288 (241)** 
Ankle RoM (deg) 26.4 (7.9) 25.1 (8.7) 25.3 (7.1)** 24.2 (8.1)** 25.1 (8.6)** 22.3 (9.5)** 
Knee RoM (deg) 69.7 (26.1) 67.8 (24.9) 67.0 (21.5)** 66.0 (21.3)** 64.8 (30.2)** 64.7 (23.5)** 
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Self-selected walking speed 
 
1.0 m/s 
 
 
Figure 1. Muscle fascicle length, MTC length and tendon length changes respectively while walking at self-selected speed and 1.0 m/s. 
Values are means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line (n=13).
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Figure 2. MTC length changes during walking at self-selected walking speed. 
Values are means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), 
DPN - dashed line (n=13). 
 
Figure 3. MTC length changes during walking at 1.0 m/s. Values are means. Line 
graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line (n=13).
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Self-selected walking speed 
 
1.0 m/s 
 
Figure 4. Knee and ankle range of motion and ankle joint moment (AJM) during stance phase while walking at self-selected walking speed 
and 1.0 m/s for healthy controls (Ctrl), diabetic patients with no neuropathy (DM), and diabetic patients with moderate/severe neuropathy 
(DPN). Values are means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line (n=13). 
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Figure 5. Achilles tendon force-elongation curves while walking at self-selected 
speed for healthy controls (Ctrl), diabetic patients with no neuropathy (DM), and 
diabetic patients with moderate/severe neuropathy (DPN). Values are means. 
Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line 
(n=13). 
 
 
Figure 6. Achilles tendon force-elongation curves while walking at 1.0 m/s for 
healthy controls (Ctrl), diabetic patients with no neuropathy (DM), and diabetic 
patients with moderate/severe neuropathy (DPN). Values are means. Line 
graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line (n=13). 
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Figure 7. Isometric plantarflexion maximal voluntary contraction (MVC) strength 
for healthy controls (Ctrl, n=23), diabetic patients with no neuropathy (DM, n=20) 
and diabetic patients with moderate/severe neuropathy (DPN, n=13). Values are 
means and SD. Significant differences from the Ctrl group are denoted by ** 
(P<0.01). 
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4.5 DISCUSSION 
This study has shown reduced Achilles tendon elongation during the loading 
phase of walking (10-70% stance) and reduced recoil during the subsequent 
propulsive phase (70-100% stance) in people with diabetes and particularly those 
with DPN compared to controls (Table 2; Fig. 1). People with diabetes and 
particularly those with DPN demonstrated a higher stiffness and hysteresis of the 
Achilles tendon measured during walking compared to the Ctrl group (Figs. 5 & 
6; Table 2). Taken together the present findings strongly indicate a reduced 
elastic energy contribution from the Achilles during walking in people with 
diabetes and particularly in those with DPN, with implications for increasing the 
metabolic CoW in patients with diabetes.  
The increased stiffness observed in the diabetes groups shows that for the same 
application of force the AT is less extensible during walking, which means that 
less energy can be stored, with less therefore available to return. The increased 
stiffness is further compounded by the fact that less force is applied on the AT in 
the DM and particularly the DPN groups (Figs. 5 & 6; Table 2). The lower tendon 
forces applied during walking in diabetic patients are the result of lower joint 
moments being developed, which reflect a natural strategy to lower the demands 
of walking (7, 8, 20). This requirement to lower the demands of walking stems 
from the lower muscular capabilities of diabetes patients, exemplified by the lower 
maximum plantarflexor strength observed in both diabetes groups (Fig. 7). The 
maximum plantarflexor strength deficits were most marked as the ankle moved 
further into dorsiflexion (Fig. 7), which is closely aligned with the position of the 
ankle during walking when the Achilles tendon is undergoing elongation (Fig. 1 & 
4). Hence, lower moments developed in dorsiflexion during walking means lower 
forces applied to elongate and store energy in the AT.  
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The results show that the MTC length changes during walking are dependent 
upon the changes in ankle and knee joint angles (Fig. 1 & 4). Although the 
magnitude of the between-group differences were relatively small (~2 deg at the 
ankle and ~4 deg at the knee), a significantly smaller ankle and knee joint range 
of motion during walking was observed in the DPN group compared to the 
controls (Fig. 4). This resulted in significantly smaller MTC length changes during 
walking in the diabetes and particularly in the DPN group compared to controls 
(Fig. 1; Table 1). The present findings of reduce tendon elongations are in line 
with previous work by Cronin et al. (11) showing that the AT length changes 
during walking are attenuated in long-term diabetic patients.   
During walking the muscle fascicles of the gastrocnemius underwent very little 
length change compared to the Achilles tendon and the MTC (Fig. 1) and they 
could be considered as acting near-isometrically. Indeed, near-isometric 
behaviour of plantarflexor muscle fascicles has been previously reported in 
healthy young populations Fuknaga (17), Lichtwark (23), Ishikawa (21), Roberts 
(37), which functions to allow the Achilles tendon to absorb the length changes 
of the MTC, thereby facilitating elastic energy storage within the tendon. Although 
the muscle fascicles were observed to actually shorten very little during the 
propulsive phase of gait in any group (Fig. 1), the reduced elastic energy 
contribution from the Achilles during walking in people with diabetes and 
particularly in those with DPN indicates that the plantarflexor muscles would need 
to contribute a greater proportion of the work, thereby increasing the metabolic 
CoW.       
The tendon stiffness data measured during walking in the present study are 
comparable with a number of previous in vivo human studies of the Achilles 
tendon measured using a dynamometry approach and reporting values ranging 
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between 149 and 207 N/mm (30, 10, 23, 26). Also, values for tendon hysteresis 
from the present study measured during walking are similar to dynamometry-
based methods reported previously in the literature for the Achilles tendon in the 
range between 5 and 26 % (30, 23, 26, 15, 22). It should be noted, that whilst 
previous studies have derived tendon stiffness and hysteresis values from static 
dynamometry measurements, the present study is unique in determining these 
tendon properties during walking. It should be acknowledged that tendon length 
changes can result from both tendon loading and also joint rotations. Therefore, 
measurements of tendon elongation in the previous and present studies reflect 
not only ‘true’ elongations resulting from tensile forces, but also elongation due 
to joint rotations. Whilst this is more easily ‘corrected’ for with the dynamometry-
based approach, the complexity of the unique approach followed in the present 
study mean that joint rotations are more challenging to account for. Nevertheless, 
the magnitudes of between-group differences in joint rotations were relatively 
small and therefore unlikely to impact on the present findings (Fig. 4; Table 1). 
Increased tendon stiffness means that the tendon will not elongate as much, and 
therefore not store as much energy. This reduced length changes is important 
because plantarflexor muscles have relatively short fibres and long tendons and 
therefore most of the length changes are achieved by lengthening and shortening 
of tendon, rather than length changes occurring within the muscle. This pattern 
of length change can be seen from presented data (most of the length changes 
occur within the tendon rather than within the muscle fascicles). 
Tendon stiffness measurements have traditionally been performed during 
isometric contractions performed on a dynamometer. Clearly these dynamometry 
measurements are more constrained as they allow control over many variables. 
For example, with dynamometry measurements there is no movement of the 
122 
 
ankle and all of the measured elongations can be attributed to the load applied 
by muscle contraction. Although measurements of tendon stiffness performed 
during gait offer high ecological validity, control over certain variables is more 
limited. For example, the ankle joint angle is not fixed, which can lead to some 
tendon elongations attributed to joint rotation rather than just the load applied to 
the tendon. Although ankle joint movement occurred during the measurements, 
the RoM in the ankle and knee were not so different between groups as to mask 
any differences found in tendon stiffness. 
The present study has shown reduced Achilles tendon elongation, increased 
stiffness and hysteresis during walking in people with diabetes compared to 
controls. The implications of these findings are a reduced storage and release of 
elastic energy from the Achilles tendon of diabetes patients during walking, 
presumably requiring a greater contribution to the work from plantarflexor 
muscles. The results strongly point towards the reduced energy saving capacity 
of the Achilles tendon in diabetes patients as an important factor contributing to 
the increased metabolic CoW in these patients. 
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5. Experimental chapter four – Vertical displacement of the 
centre of mass during walking in people with diabetes: can 
it explain a higher metabolic cost of walking? 
 
5.1 ABSTRACT 
People with diabetes display biomechanical gait alterations compared to controls 
and have an increased metabolic cost of walking (CoW), but it remains unknown 
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whether differences in the vertical displacement of centre of mass (CoM) may 
play a role in this increased CoW. Thirty-one non-diabetic controls (Ctrl); 22 
diabetic patients without peripheral neuropathy (DM) and 14 patients with 
moderate/severe DPN, underwent gait analysis using a motion analysis system 
and force plates while walking at a range of matched speeds. The aim of this 
study was to investigate CoM displacement and its relation with step length as a 
potential explanatory factor in the previously observed increased CoW with 
diabetes. Vertical displacement of the CoM was measured over the gait cycle. 
Vertical displacement of the CoM during walking was not different between 
diabetes patients with and without diabetic neuropathy compared to controls 
across the range of matched speeds examined and is therefore unlikely to be a 
factor in itself that contributes towards the increased CoW observed recently in 
people with diabetic neuropathy. The higher CoW in patients with diabetes may 
not be explained by the CoM displacement, but rather may be more related to 
shorter step lengths, increased cadence and the associated increased internal 
work and higher muscles forces developed by walking with more flexed joints. 
5.2 INTRODUCTION 
Diabetes is a global epidemic with significant morbidity and particularly common 
with increasing age (15). Diabetes is associated with a range of serious 
complications that result in reduced quality of life and premature mortality. 
Diabetic peripheral neuropathy (DPN) is one of the most severe complications of 
diabetes, occurring in 30–50% of all diabetic patients (7). DPN-related changes 
in the lower limbs lead to functional gait adaptations including taking shorter 
steps, having a higher cadence but slower self-selected and maximum walking 
speed (6, 11, 23, 30, 28, 19). Other major gait adaptations include reduced range 
of joint movement (3) and reduced muscle strength and power characteristics (6). 
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I have recently shown how the metabolic cost of walking (CoW) is higher in 
people with diabetes and particularly in those with DPN compared to controls 
(27). During walking mechanical work is done to continuously raise and lower the 
body centre of mass (CoM), which requires metabolic energy expenditure. The 
body CoM moves like an inverted pendulum during human walking, with the 
pendulum action conserving mechanical energy (1). More specifically, by keeping 
the knee relatively straight during the single leg stance phase of gait giving rise 
to the arc of the CoM, the leg supports body mass with relatively little muscle 
force. 
Like an inverted pendulum, the CoM rises/decelerates in the first half of the 
stance phase and then falls/accelerates during the second half of the stance 
phase (8, 20, 21, 31). Consequently, in the first half of the stance phase, kinetic 
energy is converted into gravitational potential energy (9), whereas in the second 
half of the stance phase, the opposite conversion occurs. During walking, the 
CoM has a sinusoidal pattern in the vertical direction with two peaks occurring. 
The first vertical peak of the CoM occurs around 30% of the gait cycle during 
single-limb stance as the CoM is ‘vaulted’ over the straight stance limb in an 
inverted pendulum manner, while the second peak occurs around 80% of the gait 
cycle during the terminal mid-stance phase.  
Increasing the CoM displacement in a type of up and down ‘bobbing’ action leads 
to an increase in the CoW compared to a normal gait (25, 22). Equally, if gait is 
manipulated to minimise or eliminate any vertical displacement of the CoM by 
walking in a ‘crouched’ style with very flexed limbs, there is an increase in the 
CoW compared to normal gait (26, 22, 14). Hence, there appears to be an 
‘optimum’ vertical displacement for the CoM in terms of its effect on the metabolic 
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CoW, where deviations from this optimum seem inefficient in terms of energy 
cost.  
Stride length also seems intrinsically linked to the CoM vertical displacement and 
the associated CoW. It has been shown that stride lengths lower than the optimal 
reduced the vertical displacement of the CoM and increased the CoW, while 
stride lengths greater than the optimal increased the CoM vertical displacement 
and increased the CoW (14). Since it is known that diabetes patients take shorter 
steps compared to controls, it might be hypothesised that that this would reduce 
the vertical displacement of the CoM, thereby increasing the CoW. Since walking 
speed may be a confounding factor in the relationship between step length and 
CoM displacement, in the present study I chose to compare the CoM 
displacement at matched walking speeds between patients with diabetes and 
controls. Therefore, this study examined the vertical displacement of the CoM 
while walking at different speeds. I hypothesised that diabetes patients have a 
reduced vertical CoM displacement that might explain previously reported finding 
of a greater CoW, with a reduced step length being a potential factor underpinning 
the suggested CoM behaviour. 
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5.3 MATERIALS AND METHODS 
Participants 
After receiving ethical approval from all relevant bodies, sixty seven participants 
gave written informed consent to participate in this study. All procedures in this 
study complied with the declaration of Helsinki. All participants were aged over 
40 years and were allocated into one of three groups: patients with diabetes and 
moderate-severe peripheral neuropathy (DPN, n=14, 14 men), patients with 
diabetes but no peripheral neuropathy (DM, n=22, 12 men) and healthy controls 
without diabetes or peripheral neuropathy (Ctrl, n=31, 19 men). All participants 
were assessed to confirm they satisfied the inclusion criteria for each group. 
Major exclusion criteria for participation in the study included peripheral vascular 
disease, musculoskeletal injury, recent surgery affecting gait, foot or lower limb 
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amputation (amputation of the hallux; amputation of more than two lesser toes on 
one foot; amputation of part of/whole foot) and open foot ulcer. Information about 
duration and type of diabetes, smoking habits and use of current medication was 
obtained via questionnaire. The majority of the DM and the DPN patients reported 
taking insulin, cholesterol-lowering medication and diabetes medication, while 
from the whole sample (including controls) only 2 people reported smoking.  
 
Assessment of peripheral neuropathy 
A clinical evaluation was undertaken to quantify peripheral neuropathy in diabetic 
patients and to confirm the absence of neuropathy in healthy controls. Peripheral 
neuropathy was assessed by using the modified Neuropathy Disability Score 
(mNDS) and the vibration perception threshold (VPT). The mNDS is a combined 
score taken from tests measuring the patient’s ability to detect temperature, pain, 
vibration and the Achilles tendon reflex (5). The VPT was assessed by placing 
the probe of the biothesiometer on the apex of the hallux and increasing the level 
of vibration until detected by the participant. A random blood glucose test was 
performed in the Ctrl group to confirm the absence of diabetes (<7 mmol/l) and 
the above neuropathy tests conducted to confirm the absence of neuropathy in 
the Ctrl group resulting from any aetiology. 
 
Gait analysis 
Participants were asked to walk along a 10-metre walkway in the gait laboratory 
at a series of standardised speeds (0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 m/s), as well as 
at their maximum walking speed. The standardised walking speeds were 
controlled by measuring the velocity of a marker attached to the sacrum after 
each trial from the motion analysis data and providing immediate feedback for 
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participants as to whether they needed to walk more quickly or more slowly on 
the next trial to achieve the required standardised speed. Participant's starting 
position was altered by the experimenters to ensure a ‘clean’ (i.e., no overlap 
outside the force platform) foot-strike on one or two of the force platforms per 
walking trial without alteration to their natural gait. Walking trials were repeated 
until at least three ‘clean’ foot contacts with the force platforms were made with 
each limb, for each speed condition. Kinematics were collected at 100 Hz using 
a 10-camera Vicon motion capture system (Vicon, Oxford, UK) positioned around 
the 10-meter walkway, tracking a full-body modified Plug-In-Gait marker set 
consisting of 54 markers. Kinetics were simultaneously collected at 1000 Hz from 
three force platforms (Kistler, Zurich, Switzerland) embedded into the middle of 
the walkway. Where possible markers were placed directly onto the skin; to 
minimise movement artefacts resulting from loose clothing all participants wore 
tight-fitting shorts and tops. All participants wore specialist diabetic shoes 
(MedSurg, Darco, Raisting, Germany) with a neutral foot-bed, ensuring the 
diabetic patients walked with safe, appropriate footwear whilst minimising the 
effect of footwear by standardising across all participants. 
 
Centre of mass displacement 
Gait variables (stride length, step length and cadence) were calculated from the 
kinematic data using Visual 3D software. The vertical displacement of the CoM 
was also measured from the kinematic data using Visual 3D software (C-motion 
Inc., MD, USA). Motion data collected during gait analysis were processed, and 
Dempster’s segment parameter model was used to calculate mass distribution 
for each body segment, thereby allowing accurate calculation of the entire body 
centre of mass. This measurement was calculated as the range of vertical 
132 
 
displacement of the CoM (Figure 1; Figure 2) during the whole gait cycle, using 
the mean of the three trials from each person. 
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to 
assess between group differences. If the ANOVA was significant, a Fisher’s least 
significant difference (LSD) post-hoc test was used to test for differences between 
the diabetes groups (DM and DPN) and the control group. All values presented 
are means and standard deviation. Significance was set at p<0.05. 
 
 
5.4 RESULTS 
Participant characteristics  
There were significant differences between the groups in age, body mass and 
BMI, which were significantly greater in the DPN group (Table 1, p<0.01). 
 
Neuropathy assessments  
As expected, the DPN group displayed significantly higher values for the VPT 
and the mNDS compared to the Ctrl group (Table 1). The VPT and mNDS for the 
DM group were not significantly different from the Ctrl, underlining that this 
diabetic patient group had no neuropathy (Table 1). 
 
Step length and cadence 
The DPN group displayed significantly shorter step lengths in all given speeds 
compared to Ctrl group (Table 2). The DPN group had significantly higher 
cadence in all given speeds compared to Ctrl group. 
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Centre of mass displacement at different speeds 
There were significant differences in the CoM displacement between the groups 
only at maximum walking speed, where the DPN group expressed greater vertical 
displacement of the CoM (Fig. 1). 
 
 
 
 
 
Table 1. Participant characteristics and results from neuropathy assessments. 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 56 (10) 51 (9)** 66 (14)** 
Body mass (kg) 76 (10) 80.5 (12) 91.5 (18)** 
Height (m) 1.72 (0.12) 1.71 (0.09) 1.73 (0.11) 
BMI (kg/m2) 26 (3) 28 (4) 31 (4)** 
NDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3.4) 8.2 (3.4) 27.4 (9.1)** 
Diabetes duration (years) - 14 (12) 14 (11) 
Type 1 diabetes - 7 4 
Type 2 diabetes - 15 10 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) 
and diabetic patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by ** (P<0.01). BMI = body mass 
index, NDS = neuropathy disability score, VPT = vibration perception threshold. 
Values are means (standard deviations). 
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Table 2. Temporal-spatial gait parameters. 
    Variable Group 
 Ctrl  DM DPN 
0.6 m/s    
Step length (m) 0.59 (0.12) 0.57 (0.12) 0.51 (0.09)** 
Cadence (steps/m) 108 (0.61) 108 (0.74) 113 (0.41)** 
0.8 m/s    
Step length (m 0.63 (0.14) 0.57 (0.12) 0.53 (0.15)** 
Cadence (steps/m) 112 (0.84) 113 (0.67) 116 (0.68)** 
1.0 m/s    
Step length (m) 0.69 (0.15) 0.67 (0.05) 0.64 (0.04)* 
Cadence (steps/m) 117 (1.12) 119 (1.08) 122 (1.25)** 
1.2 m/s    
Step length (m) 0.76 (0.11) 0.75 (0.17) 0.69 (0.07)* 
Cadence (steps/m) 124 (1.16) 125 (1.27) 128 (1.08)** 
1.4 m/s    
Step length (m) 0.79 (0.12) 0.77 (0.17) 0.71 (0.11)* 
Cadence (steps/m) 127 (1.56) 129 (1.47) 131 (1.49)** 
1.6 m/s    
Step length (m) 0.81 (0.11) 0.80 (0.04) 0.74 (0.02)* 
Cadence (steps/m) 129 (0.98) 132 (0.48) 135 (0.63)** 
Maximum walking speed 
(m/s) 
Step length (m) 
1.92 (0.11) 
0.85 (0.07) 
143 (1.18) 
1.88 (0.16)** 
0.79 (0.06)* 
140 (1.27)* 
1.68 (0.22)** 
0.78 (0.12)** 
129 (0.98)** 
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Cadence (steps/m) 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) 
and diabetic patients with moderate/severe neuropathy (DPN, n=14). Significant 
differences from the Ctrl group are denoted by *(P<0.05) or **(P<0.01). Values 
are means (standard deviations). Gait parameters were collected on the 
laboratory walkway. 
 
Figure 1. Centre of mass (CoM) vertical (Z) displacement across walking speeds 
from 0.6 to 1.6 m/s and maximum walking speed for healthy controls (Ctrl; n=31), 
diabetic patients with no neuropathy (DM; n=22) and diabetic patients with 
moderate/severe neuropathy (DPN; n=14). Values are group means and SD; ** 
denotes significantly (P<0.01) different from the control group. 
 
 
Figure 2A. Example trace from one participant showing the vertical displacement 
of the CoM over the gait cycle. ↑ start of double support phase, ↑↑ end of single 
support phase (start of double support phase), ↑↑↑start of swing phase 70%. 
136 
 
 
Figure 2B. Schematic illustration of the rise and fall of the CoM during the gait 
cycle. 
 
 
 
 
 
 
 
5.5 DISCUSSION 
This study has shown that the vertical displacement of the CoM during walking is 
not different between diabetes patients with and without diabetic neuropathy 
compared to controls across a range of matched speeds (Fig. 1) and is therefore 
unlikely to be a factor in itself that contributes towards the increased CoW 
observed recently in people with diabetic neuropathy (27). The exception to this 
was at maximum walking speed where patients with diabetes and those with 
diabetic neuropathy showed an increased or a decreased CoM displacement 
respectively compared to controls (Fig 1).  
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It has previously been shown that stride lengths shorter and longer than the 
optimum lead to reduced and increased CoM displacements respectively, 
increasing the metabolic CoW in both situations (14). In that study subjects 
increased their metabolic cost when they reduced their vertical CoM movement 
by taking shorter strides. Subjects also expended more metabolic energy when 
they walked with greater stride length than their preferred stride length. Previous 
work (13) has shown that as stride length increases, metabolic energy 
expenditure and mechanical work performed on the CoM also increase. This is 
not caused by CoM displacement per se but rather by the additional negative 
work performed to redirect the CoM velocity during step-to-step transitions and 
by positive work to restore the energy lost. Although I did find consistently shorter 
step lengths across matched walking speeds in patients with diabetes and 
particularly those with diabetic neuropathy, this did not alter the vertical 
displacement of the CoM (Fig. 1). The lack of effect of stride shortening on the 
CoM might be due to the fact that people with diabetes and neuropathy have 
adapted to a different optimal step length, which is consistently shorter compared 
to controls across the range of speeds examined, or that they have adopted a 
different step length based on the total metabolic CoW rather than the cost 
associated with CoM displacement. The exception to this was at maximum 
walking speed where the CoM displacement was different in both diabetes groups 
compared to controls (Fig. 1). Both diabetes groups took shorter steps compared 
to controls, but the DPN group displayed an increased CoM displacement, while 
the DM group displayed a decreased CoM displacement. This might reflect the 
fact that asking people with diabetes to walk as fast as they can disturbs the 
normal regulatory control that they exert over gait and may force them to adopt 
stratgeies that are suboptimal in terms of energy efficiency. This is supported by 
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the observation that all groups adapted to increased walking speeds between 0.6 
and 1.6 m/s by increasing cadence, whereas in the transition from walking at 1.6 
m/s to maximum walking speed the DPN group were unable to increase cadence 
any further and instead needed to increase step length, presumably 
compromising the optimal step length (Table 2). 
Consistent with the shorter steps taken by both diabetes groups compared to 
controls was the higher cadence required to meet the required matched walking 
speeds by the diabetes patients (Table 2). An increased cadence in the diabetes 
groups would require greater internal work from the muscles to move the legs 
during walking (24). Although I have previously found the joint work developed 
during a single stance phase to be lower in patients with diabetes and even more 
so in those with diabetic neuropathy, this would be repeated more often over a 
given distance in diabetes patients because of a higher cadence. Therefore, a 
higher cadence for any given walking speed could explain the higher CoW 
previously reported in patients with diabetes and those with diabetic neuropathy 
(27). 
In the absence of differences in the CoM displacement, another possible 
explanation for the higher CoW previously reported in diabetes patients is that 
they might be producing greater muscle force without performing as much joint 
work per stance phase. This would be consistent with previous reports from 
walking with a ‘crouched gait’ by excessively flexing the joints (26, 22). Diabetes 
patients were observed to walk with shorter steps, which is known to be achieved 
by greater flexion in the lower limb joints. This likely gives rise to higher muscle 
forces to sustain the more flexed joint positions as previously observed (29) and 
consequently a higher metabolic CoW. Therefore, the effective mechanical 
advantage (muscle force moment arm/ground reaction force moment arm) may 
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be worse in diabetic patients, which would mean that more muscle force would 
be required to overcome the moment of the ground reaction force – hence higher 
CoW. This factor may also explain why/how diabetes patients have adopted 
“optimum” CoM displacement per stride length as a strategy to minimise CoW 
(meaning unaltered compared to controls). This relates to the Achilles tendon, 
which plays a major role in energy saving during walking under ‘normal’ 
circumstances (2). Gordon et al. (14) presented in their study a manipulation of 
step length above and below the optimal, and found that the CoM vertical 
displacement increases and decreases over that observed at the self-selected 
step length. Both increased and decreased vertical displacement of the CoM 
beyond were associated with a higher energy cost compared to that observed at 
self-selected step length, suggesting an optimal vertical displacement of the CoM 
where energy cost is minimised. 
 In my opinion the main issues determining the CoW are higher cadence and 
higher cumulative joint work, stiffer Achilles tendon with higher hysteresis, 
potentially co-activation (it is hypothesized but not measured). There are many 
factors, not just one, but maybe one of the most important factors is related to 
stiffer tendons because these tendons might also cause some of the other 
reported factors such as shorter steps, longer contact time, lower joint moments, 
smaller RoM and smaller elongation. It is difficult to say for sure that these 
relations are causative or just correlative; one way to prove this would be to 
manipulate stride length and cadence, one by one in some systematic way in 
healthy participants to see what effect they might have. A future study might use 
some form of regression analysis in terms of defining one potential factor 
responsible for a higher CoW, but this analysis would need 10 participants for 
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every variable entered into a regression analysis and would therefore need more 
participants. 
In my opinion stiffer tendons are maybe one of the most important factors in the 
higher CoW and it can be compared with driving a car with flat tires that will just 
increase fuel consumption, i.e. CoW.  
My idea about improving efficiency of walking is that it will not be achieved just 
by performing any kind of aerobic exercises while still driving with flat tires (stiffer 
tendons), but also through appropriate stretching training with the aim of 
increasing tendon compliance. Increasing flexibility of plantar muscles would also 
allow them to store and release more energy and as a logical consequence would 
be longer steps, shorter contact times and lower cadence. 
To best of our knowledge this is the first study that has investigated the CoM 
displacement during walking in a diabetic population. It could be considered as a 
limitation of the present study that body mass was significantly different between 
groups. However, the higher body mass of patients with diabetes (especially 
those with DPN) is a well-known characteristic of this population described in the 
literature (19, 17, 16) and is unlikely to have directly affected the CoM vertical 
displacement. If anything it might be expected that increased body mass might 
reduce the extent to which the CoM is displaced, but this was not found in the 
present study indicating that group differences body mass did not influence the 
present results. Although only a mean of 10 years difference, patients in the DPN 
group were significantly older than controls (66 to 56 years, respectively), which 
might be a confounding factor for some of the variables examined. 
I have shown that there are no differences in the vertical displacement of the CoM 
in patients with diabetes compared with controls when walking speed is matched, 
with the exeption of the maximum walking speed. The higher CoW in patients 
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with diabetes may not be explained by the CoM displacement, but rather may be 
more related to shorter step lengths, increased cadence and the associated 
increased internal work and higher muscles forces developed by walking with 
more flexed joints. 
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6. Conclusions & future directions 
  
Summary of main findings 
 
The main aim of this thesis was to investigate the cost of walking in people with 
diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN) and to examine 
the biomechanical factors that could contribute to explaining any potential 
differences. The work for this thesis investigated level walking as a part of 
everyday life activities. Although there is a wide base of research that had been 
investigating gait patterns in the diabetic population, this is the first body of work 
that has investigated the energy cost of walking (CoW) in people with diabetes. 
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In chapter two it was observed that DPN patients have shorter steps, longer 
single limb stance time, lower concentric work and higher energy cost of walking 
when walking speed is matched. The lower concentric joint work in patients with 
diabetes might be a consequence of kinematic gait alterations and may represent 
a natural strategy aimed at minimizing the CoW. This ‘altered gait strategy’ in 
people with diabetes enables them to meet the task demands in the face of 
compromised musculoskeletal properties and already elevated CoW due to 
energetic inefficiencies. The main finding of this chapter is that people with 
diabetes and diabetic peripheral neuropathy have a higher CoW when the 
walking speeds are matched. This finding is likely due to energetic inefficiencies 
associated with diabetes and DPN reflecting physiological and biomechanical 
characteristics as well as the cumulative effect of potentially higher joint work over 
a given time/distance due to higher cadence. It was surprising that diabetic 
patients were actually able to match the same walking speed as controls despite 
generating significantly reduced lower limb joint work. The same lower limb joint 
work was associated with a higher CoW in diabetic patients and particularly in 
patients with DPN, which can be observed in Fig. 5. Schenau and Cavanagh (14) 
concluded that there are no models available which predict reliable measures for 
positive and negative power from active elements of individual muscles and their 
efficiencies and that joint work cannot be used as a reliable measure for a 
prediction of the CoW. Another contributing factor to the higher CoW in the DPN 
group may be the increased step frequency (the DPN group had a shorter step 
length for a given speed, therefore requiring a higher step frequency). These two 
factors (lower limb joint work and higher step frequency) would increase the 
internal work required for moving the lower limbs and may contribute to a higher 
CoW in people with diabetes and particularly those with DPN. For human walking, 
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gross cost of transport is U-shaped. Although theoretically self-selected speed 
should be on the bottom of the U-shaped curve that is not always the optimum 
speed of moving which reflects the minimal energy expenditure during the 
walking. 
In the third chapter I have presented that diabetic patients and especially those 
with DPN displayed increased effective mechanical advantage (EMA) and 
smaller external moment arm (ExtMA) at the ankle across all walking speeds. 
The increased EMA was mainly caused by a smaller external moment arm of the 
ground reaction force in the DPN and DM groups compared to Ctrl. The DPN 
group reduced the joint moment at the ankle during walking by applying the 
ground reaction force more proximally on the foot, or at an angle directed more 
towards the ankle, thereby reducing the external moment arm and increasing the 
EMA around the ankle. 
Another finding of this chapter was the reduced lower limb range of motion (RoM) 
during walking in diabetic patients compared with controls. This was achieved via 
shorter steps taken by diabetic patients during walking. It is known that DM and 
DPN patients are able to lower joint moments and walk with shorter steps, and 
this translates to less flexed joints, which in general means that the moment arms 
of the ground reaction force are smaller compared with the situation with more 
flexed joints. These findings demonstrate a mechanism through which people 
with diabetes and particularly those with DPN reduce the joint moment at the 
ankle during walking – by applying the GRF more proximally on the foot or at an 
angle more towards the ankle, reducing the ExtMA around the ankle and thereby 
reducing the ankle joint moment. The increased effective mechanical advantage 
(EMA) was mainly caused by a smaller ExtMA in the DPN and DM groups 
compared to Ctrl. Whilst the total hip joint RoM during walking was reduced in 
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diabetes patients and especially those with DPN compared to controls, patients 
with diabetes and to the greatest extent those with DPN flexed the hip more than 
controls. This kinematic strategy fits very well with the ‘hip strategy’ previously 
reported in other studies (10, 13), whereby diabetes patients have been observed 
to ‘drag’ the leg forwards into the swing phase from the hip, rather than ‘propelling’ 
the leg off from the ground using the ankle plantarflexors.  
In chapter four I have shown the consequent reduction in the force applied to the 
Achilles tendon (AT) would result in reduced tendon elongation and therefore 
reduced storage of elastic strain energy in the diabetic population. The reduced 
contribution from elastic strain energy stored in the Achilles tendon could impact 
upon the gait mechanics and efficiency. My main findings are a smaller MTC 
length change, increased stiffness and hysteresis of the Achilles tendon in the 
DPN group compared to the control group. A stiffer tendon will reduce storage 
and release of energy from the AT. One of the causes might be non-enzymatic 
glycation of tissues and it might contribute to explaining the altered lower limb 
biomechanics, especially the limited ankle and knee RoM in people with diabetes, 
higher cadence, shorter steps, longer contact time and lower ankle joint 
moments.  
In chapter five I investigated the role of the vertical centre of mass (CoM) 
displacement during walking and its potential impact on the CoW. The main 
finding of this chapter shows that it is not the CoM displacement itself that is 
contributing to increased energy cost, but it is more likely linked to step length 
and cadence alterations i.e. although diabetic patients were able to generate 
reduced lower limb joint work (Chapter 2) they displayed increased step 
frequency which cumulatively might increase metabolic cost of walking. The 
vertical displacement of the centre of mass seems to be minimised by the DPN 
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group around the speeds associated with self-selected walking speed i.e., 1 and 
1.2 m/s. 
Considering findings in all four experimental chapters I suggest that the major 
factors contributing to the increased energy CoW in patients with diabetes and 
DPN must include shorter strides and increased cadence for their effect on 
internal work and also a reduced energy contribution from the Achilles tendon. 
The work for this thesis was the first to address all of these issues in people with 
diabetes in order to try to give us a broader picture of the energy CoW in people 
with diabetes and especially diabetic peripheral neuropathy and to understand 
the biomechanical factors influencing the CoW.  
Another potential factor is the role of the muscle co-activation. Although I have 
not assessed muscle co-activation in the work for this thesis, if increased it would 
contribute to a greater energy consumption by the muscles. 
The main findings of this thesis are that, when the walking speed is matched, 
people with diabetes and diabetic peripheral neuropathy walked with shorter 
strides, longer contact time with the ground, smaller external moment arms, 
smaller range of motion at the ankle, knee and hip, higher cadence, lower ankle 
joint moments, having weaker plantarflexors, producing lower positive muscle 
work, altered muscle-tendon behaviour with less energy stored in their tendons. 
The data indicates that each group choose to walk at a self-selected speed where 
the energy expenditure was optimal. Other important findings are significant 
differences in maximal walking speeds where the DPN group walked slower than 
the Ctrl group. The maximum walking speed was highest in controls, lower in 
patients with diabetes and lower still in patients with DPN. The maximum walking 
speed attainable might be considered as a useful indicator of physical capacities 
and this could be useful focus for future studies. 
149 
 
The methods used to quantify oxygen uptake during walking are good and 
certainly well established with good reliability (ICC > 0.80) (12, 3, 1, 11, 4). 
In terms of the statistical analysis of the results in the present thesis, it could have 
been argued to perform a two-way analysis of variance (ANOVA) with group (3 
levels) and walking speed (6 levels) as the two independent variables to avoid 
performing repeated tests with a one-way ANOVA. However, the output from the 
two-way ANOVA would be a main effect for speed, a main effect for group and 
an interaction effect. The results from the two main effects would not be of interest 
since they would take an average of the other main independent variable in giving 
an output for the other. To answer the specific hypotheses set out in the present 
thesis, multiple comparisons would have needed to be performed using post-hoc 
tests within the interaction effect. There might be an argument to state that some 
kind of adjustment for multiple comparisons could have been performed to adjust 
the alpha level. One such test is the Bonferroni correction, however this is a very 
conservative method that divides alpha level by number of comparisons and 
conversely increases the likelihood of making a type 2 error. It should also be 
considered that the analysis of the results were hypothesis-driven and not simply 
to find any possible differences from any number of possibilities. As a 
compromise if I accepted significance only for p-values of below 0.01, very few 
variables would drop out of significance and further this is in line (although not as 
conservative) with the principals of tests to adjust for multiple comparison.. 
Also, the other possibility to sub-divide the controls in similar age groups as the 
diabetics with and without neuropathy was not considered because it would bring 
the group numbers down to very small numbers, which would result in a loss of 
statistical power.  
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Further findings of interest and future directions 
Type 2 diabetes typically affects patients who are overweight and display a lower 
level of physical activity, but evidence suggests that stressful experience might 
affect diabetes, both its onset and its exacerbation. A higher CoW in people with 
diabetes may underpin the lower physical activity levels and lower habitual 
walking distances in this population and may also contribute towards a negative 
spiral where there is a greater perception of difficulty for walking, which causes 
less engagement in physical activity (6, 9, 14, 15, 16), leading to poorer metabolic 
control and worsening of the diabetic condition. To allow intervention to break this 
negative cycle, it is therefore important to understand the factors that contribute 
to increasing the CoW in diabetes. 
I found that stride length and cadence seem to be important factors in terms of 
the cumulative amount of work done for its effects on the CoW and future studies 
might try to manipulate stride length to see how that influences the CoW when 
the stride length is matched between Ctrl and DM and DPN patients and to 
compare the CoW. Possible interventions to reduce the CoW would be to alter 
tendon stiffness through appropriate stretching training with the aim of increasing 
tendon compliance. Increasing flexibility of lower limb muscles would also allow 
them to store and release more energy and as a logical consequence would be 
longer steps, shorter contact times and lower cadence. Furthermore, a measure 
of muscle co-activation, through EMG with appropriate normalization, would be 
useful in further studies and would be able to determine if the efficiency of the 
muscle is compromised.  
In relation to balance it might be interesting to investigate potential differences in 
the CoW between people with diabetes and poor balance control compared to 
those with diabetes but with better balance control. We might hypothesise that 
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instability and the associated corrections needed could increase the CoW. This 
might be challenging since we know (1) balance is impaired to a greater extent in 
people with DPN, so apportioning appropriate groups could be a challenge. 
 
Considerations and limitations 
A higher level of co-activation from agonist-antagonist muscles is a potential 
candidate for contributing towards the higher CoW observed in people with 
diabetes as it is presented previously (5, 7, 8). This important aspect was not 
assessed in the present work for this thesis, but future work should address this 
issue by measuring the level of co-activation from lower limb muscles and also 
relating this level of activation to the maximal activation capacity of the same 
muscles. In the present thesis, although walking speed was matched between 
groups, step length was free to vary and as discussed could have been one of 
the factors contributing to the increased CoW observed in diabetes patients. 
Future work might try to match step length while evaluating the impact on the 
CoW in patients with diabetes. However, this approach may also face the 
confounding effect of walking speed, since matching both step length and walking 
speed might approach the limits of some patient’s capabilities. In terms of the 
participant characteristics for the work composing this thesis, although only a 
mean of 10 years difference, patients in the DPN group were significantly older 
than controls (66 to 56 years, respectively), which might be a confounding factor 
for some of the variables examined. I did not measure blood lactate, which might 
have been particularly relevant to Chapter 2 for confirming that all participants 
were working below their lactate threshold. This is a consideration since the VO2 
slow component is much more pronounced during exercise above the lactate 
threshold compared to below. Since a number of inefficiencies relating to the 
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CoW in patients with diabetes may relate to the muscle, future work might 
investigate the muscular causes of the increased CoW at a cellular level. 
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